Christopher R Flowers, M.D., M.S.

Peer-Reviewed Articles

1. Li, R, Yang, P, Di Pilato, M, Zhang, J, Flowers, CR, Shang, L, Li, Z. Accurate imputation of pathway-specific gene expression in spatial transcriptomics with PASTA. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41397970.
2. Luo, Z, Li, M, Primeaux, B, Shah, R, Lin, R, Iyer, SP, Nastoupil, L, Green, M, Westin, JR, Flowers, CR, Chihara, D. Clinical trial success rate in lymphoma. Blood Advances 10(5):1713-1721, 2026. e-Pub 2026. PMID: 41201381.
3. Kim K, Shah R, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil LJ, Westin JR, Flowers CR, Neelapu SS, Chihara D. Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma. Br J Haematol 208(3):992-1000, 2026. e-Pub 2026. PMID: 41521615.
4. Ruan J, Chen Z, Larson MC, Bennani NN, Allen PB, Mou E, Wallace DS, Mehta-Shah N, Lossos IS, Malpica Castillo LE, Jaye DL, Vega F, Inghirami GG, Pongas GN, Akkad N, Casulo C, Martin P, Cohen JB, Habermann TM, Maurer MJ, Leonard JP, Friedberg JW, Kahl BS, Cerhan JR, Flowers CR, Feldman AL. Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study. Blood Adv, 2026. e-Pub 2026. PMID: 41707114.
5. Yang H, Arita K, Bowman K, Chihara D, Henderson J, Rost G, Rojas E, Parsons S, Lakra P, Abedin A, Neelapu SS, Strati P, Nastoupil LJ, Fayad L, Iyer SP, Rodriguez A, Hagemeister FB, Malpica L, Lee HJ, Hilton L, Scott DW, Davis RE, Flowers CR, Westin JR, Inghirami G, Vega F, Green MR. A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma. bioRxiv, 2026. e-Pub 2026. PMID: 41648221.
6. Thompson C, Trneny M, Morschhauser F, Salles G, Reagan PM, Hertzberg M, Zhang H, Thieblemont C, Hu B, Fonseca G, Kim WS, Martelli M, Mehta A, Singh A, Yan M, Hirata J, Sugidono M, Lee C, Sharman JP, Mehta-Shah N, Flowers CR, Tilly H, Chua N, Casasnovas RO, Miall F, Kim TM, Tsai XC, Nasta S, Lee ST, Friedberg JW. PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study. Blood 147(3):254-265, 2026. e-Pub 2026. PMID: 40997297.
7. Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquieres H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janikova A, Mocikova H, Furst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. J Clin Oncol 44(2):117-128, 2026. e-Pub 2026. PMID: 41329901.
8. Nguyen, TM, Lu, J, Guffey, D, Kim, RB, Oluyomi, AO, Rosales, O, Bandyo, R, Miller-Chism, CN, Udden, MM, Mims, MP, Abuasab, T, Diamond, A, Teegavarapu, PS, Nze, CC, Flowers, CR, Li, A, Jiang, JY. Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System. Clinical Lymphoma, Myeloma and Leukemia 26(1):e12-e20.e5, 2026. e-Pub 2026. PMID: 40946017.
9. Toumeh, N, Larson, MC, Negaard, B, Casulo, C, Ahmed, S, Maurer, MJ, Feldman, AL, Mou, E, Cohen, JB, Habermann, TM, Chihara, D, Lossos, IS, Friedberg, JW, Kahl, BS, Martin, P, Flowers, CR, Cerhan, JR, Williams, A, Rosenthal, AC, Ainsworth, A, Thompson, CA, Durani, U. Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients. Leukemia and Lymphoma 67(1):190-197, 2026. e-Pub 2026. PMID: 41178593.
10. de Paz AM, Chin CR, Ketavarapu M, Sun Y, Marunde MR, Chang JT, Khan L, Cohen J, Yang R, Bale MJ, Daman AW, Kumar VE, Jiang C, Ahimovic DJ, Owyong M, Ravishankar A, Wong W, Shih R, Graham B, Smith CE, Karagianidis I, Cerchietti L, Flowers CR, Green MR, Mason CE, Sun JC, Martin-Trujillo A, Niec RE, Long Y, Keogh MC, Liu S, Beguelin W, Leslie CS, Melnick AM, Josefowicz SZ. Signaling induced biophysical disruption of repressed chromatin domains drives immune cell fate. bioRxiv, 2025. e-Pub 2025. PMID: 41427328.
11. Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 43(35):3698-3705, 2025. e-Pub 2025. PMID: 40991874.
12. Atallah-Yunes, SA, Nze, CC, King, RL, Rees, MJ, Alderuccio, JP, Watkins, MP, Kahl, BS, Easwar, N, Yamshon, S, Ravindra, A, Farooq, U, Rosenthal, AC, Munoz, J, Rojas-Neira, EM, Ayers, AA, Moustafa, MA, Habermann, TM, Witzig, TE, Ansell, SM, Nowakowski, GS, Koff, JL, Flowers, CR, Wang, Y. Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma. American journal of hematology 100(12):2185-2194, 2025. e-Pub 2025. PMID: 40899786.
13. Mondello, P, Negaard, B, Feldman, AL, Link, BK, Casulo, C, Chihara, D, Russler-Germain, D, Romancik, JT, Gribbin, C, Haddadi, S, Mou, E, Micallef, IN, Johnston, PB, Novak, J, Wang, Y, King, RL, Novak, AJ, Habermann, TM, Martin, P, Kahl, BS, Nowakowski, GS, Nastoupil, L, Cerhan, JR, Flowers, CR, Lossos, IS, Richard Burack, W, Maurer, MJ, Ansell, SM. Subsets of follicular lymphoma 3B have divergent outcomes. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40781119.
14. Strati, P, Feng, L, Westin, JR, Nair, R, Fayad, LE, Rodriguez, MA, Chihara, D, Malpica Castillo, LE, Henderson, J, Gallardo, M, Rivera, M, Wang, I, Bolshakova, A, Radko, A, Kurtz, DM, Alig, S, Flowers, CR, Alizadeh, AA, Neelapu, SS. Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40775236.
15. Superdock MA, Rimsza LM, Wallace DS, Strawderman M, Ramsower CA, Steiner RE, Faugh T, Maurer MJ, Link BK, Rosenthal AC, Burack WR, Syrbu SI, Feldman AL, Rock PJ, Robetorye RS, Cerhan JR, Flowers CR, Friedberg JW, Casulo C. Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study. Leuk Lymphoma 66(12):2324-2327, 2025. e-Pub 2025. PMID: 40768371.
16. Wang, W, Cai, Q, Liu, Y, Nie, L, Lee, H, Yan, F, Fei, Y, Yao, Y, Li, Y, Tan, L, Lorenzi, PL, Wang, Y, Yao, J, Chen, Z, McIntosh, J, Yu, CT, Jain, P, Jiang, VC, Vargas, J, Li, X, Zhang, T, Li, S, Santos, DA, Thirumurthi, S, Seeley, E, Simon, LM, Flowers, CR, Ok, CY, Wang, L. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood 146(21):2544-2560, 2025. e-Pub 2025. PMID: 40700581.
17. Dai, Y, Kizhakeyil, A, Chihara, D, Li, X, Liu, Y, Sainz Zuniga, TP, Wilson, A, Henderson, J, Vibe, D, Petrosyants, A, Jacobson, CA, Sarachakov, A, Nomie, K, Kryukov, K, Bagaev, A, Chauhan, A, Westin, JR, Flowers, CR, Vega Vazquez, F, Wang, L, Green, M. Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma. Nature Genetics 57(11):2715-2727, 2025. e-Pub 2025. PMID: 41120574.
18. Cerhan, JR, Sokolova, T, Cahn, EJ, Tsang, M, Strouse, CS, Hildebrandt, MA, Rosenthal, AC, Feldman, AL, Jaye, DL, Martin, P, Cohen, JB, Kahl, BS, Lossos, IS, Friedberg, JW, Nastoupil, L, Link, BK, Habermann, TM, Maurer, MJ, Casulo, C, Thompson, CA, Williams, A, Flowers, CR. Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort. Hematological Oncology 43(6), 2025. e-Pub 2025. PMID: 41057230.
19. Xiang, JJ, Cheng, L, Canavan, ME, Lin, JK, Hui, D, Ratan, R, Flowers, CR, Niu, J, Zhao, H, Giordano, SH, Adelson, K. Association of systemic anticancer treatment (SACT) with end-of-life (EOL) healthcare use among older patients with hematologic malignancies. JCO Oncology Practice 21:306, 2025. e-Pub 2025.
20. Strati, P, Brandt, AC, Lionel, A, Henderson, J, Westin, JR, Adkins, S, Shpall, E, Kebriaei, P, Ramdial, JL, Saini, N, Ahmed, S, Flowers, CR, Neelapu, SS, Hildebrandt, MA. Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy. Journal for immunotherapy of cancer 13(10), 2025. e-Pub 2025. PMID: 41067879.
21. Strati, P, Feng, L, Tyshevich, A, Shavronskaya, D, Alesse, JE, English, N, Sheehan, E, Syzrantsev, N, Nesmelov, A, Zhuang, TZ, Chihara, D, Westin, JR, Ahmed, S, Fayad, LE, Henderson, J, Dent, K, McChesney, E, Neelapu, SS, Flowers, CR. A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research 31(19):4079-4088, 2025. e-Pub 2025. PMID: 40729376.
22. Akkad, N, Feng, L, Westin, JR, Hagemeister, FB, Lee, HJ, Fayad, LE, Ahmed, S, Nair, R, Rodriguez, MA, Strati, P, Chihara, D, Flowers, CR, Claret, LC, Ibanez, K, Wang, L, Fowler, N, Henderson, J, Davis, RE, Neelapu, SS, Green, M, Nastoupil, L. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
23. Chang, A, Pelletier, AN, McGuire, DJ, Tsagiopoulou, M, Karipidou, M, Ayers, AA, Leal, AM, Churnetski, MC, O'Leary, CB, Switchenko, JM, Davis, CW, Frank, DA, Koff, JL, Cohen, JB, Sekaly, RP, Stamatopoulos, K, Flowers, CR, Ahmed, R. PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. Proceedings of the National Academy of Sciences of the United States of America 122(36), 2025. e-Pub 2025. PMID: 40906805.
24. Saha, S, Rehman, L, Rehman, A, Darbaniyan, F, Weber, DM, Becnel, M, Gaballa, MM, Thomas, SK, Lee, HC, Chang, C, Arora, R, Menges, M, Corallo, SA, Davila, ML, Locke, FL, Tanner, MR, Neelapu, SS, Shpall, E, Flowers, CR, Orlowski, R, Jenq, RR, Jain, MD, Peterson, CB, Hansen, DK, Saini, N, Patel, K. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Advances 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
25. Li, X, Singhal, K, Deng, Q, Chihara, D, Russler-Germain, D, Harkins, RA, Henderson, J, Arita, K, Kizhakeyil, A, Sun, R, Lakra, P, Hussein, UK, Foltz, JA, Wilson, A, Schmidt, E, Nizamuddin, I, Dinh, T, Kesaraju, A, Hamilton, MP, Allen, CE, Gandhi, MK, Tobin, J, Jiang, A, Hilton, L, Scott, DW, Vega Vazquez, F, Flowers, CR, Westin, JR, Griffith, OL, Fehniger, TA, Griffith, M, Green, M. Large B cell lymphoma microenvironment archetype profiles. Cancer cell 43(7):1347-1364.e13, 2025. e-Pub 2025. PMID: 40920660.
26. Yang, H, Zhang, W, Ravanmehr, V, Cui, G, Bowman, K, Chen, R, Henderson, J, Lockman, S, Rojas, E, Wilson, A, Parsons, S, Mechaly, A, Regad, L, Haouz, A, Flowers, CR, Neelapu, SS, Nastoupil, L, Davis, RE, Deng, Q, Rodrigues-Lima, F, Green, M. Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement. Blood 146(2):191-205, 2025. e-Pub 2025. PMID: 40090010.
27. Trneny, M, Fogliatto, L, Gardner, F, Flinn, IW, Larouche, JF, Haioun, C, Canales, M, Goto, H, Hajek, R, Salles, G, Singh, A, Yan, M, Kothari, R, Man, G, Sahin, D, Hirata, J, Lee, C, Tilly, H, Flowers, CR. Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes. Blood Advances 9(13):3263-3267, 2025. e-Pub 2025. PMID: 40088467.
28. Shneider, NA, Nesta, AV, Rifai, OM, Yasek, J, Elyaman, W, Aziz-Zaman, S, Lyu, M, Levy, S, Hoover, BN, Vlad, G, Huang, M, Zeng, K, Sadeghi, T, Reddy, A, Flowers, CR, Parmar, S. Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS. NEJM Evidence 4(5), 2025. e-Pub 2025.
29. Shneider NA, Nesta AV, Rifai OM, Yasek J, Elyaman W, Aziz-Zaman S, Lyu MA, Levy SHS, Hoover BN, Vlad G, Huang M, Zeng K, Sadeghi T, Reddy A, Flowers CR, Parmar S. Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS. NEJM Evid 4(5):EVIDoa2400249, 2025. e-Pub 2025. PMID: 40261116.
30. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Xu G, Deswal A, Iliescu C, Badillo M, Ky M, Avellaneda M, Tangc G, Medeiros LJ, Vega F, Flowers CR, Wang ML. Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. Leuk Lymphoma 66(5):956-960, 2025. e-Pub 2025. PMID: 39838574.
31. Chihara, D, Steiner, RE, Nair, R, Feng, L, Ahmed, S, Strati, P, Malpica Castillo, LE, Griffith, D, Mathew, SA, Montinez, W, Masand, G, Samaniego, F, Rodriguez, MA, Hagemeister, FB, Fayad, LE, Iyer, SP, Nastoupil, L, Neelapu, SS, Flowers, CR, Westin, JR. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Advances 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
32. Yamshon, S, Koff, JL, Larson, MC, Kahl, BS, Casulo, C, Lossos, IS, Haddadi, S, Stanchina, M, Chihara, D, Ayers, AA, Habermann, TM, Wang, Y, Khurana, A, Nowakowski, GS, Reicks, TW, Farooq, U, Link, BK, Cohen, JB, Martin, P, Li, J, Shewade, A, Batlevi, CL, Lo-Rossi, A, Fox, D, Masaquel, A, Mun, Y, Cerhan, JR, Flowers, CR, Maurer, MJ, Nastoupil, L. Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx. American journal of hematology 100(4):606-615, 2025. e-Pub 2025. PMID: 39918101.
33. Long, JP, Prakash, R, Edelkamp, P, Knafl, M, Lionel, AC, Nair, R, Ahmed, S, Strati, P, Malpica Castillo, LE, Al Zaki, A, Chien, KS, Chihara, D, Westin, JR, Khawaja, F, Nastoupil, L, Mulanovich, VE, Futreal, A, Woodman, SE, Daver, N, Flowers, CR, Neelapu, SS, Manzano, JM, Iyer, SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Network Open 8(4), 2025. e-Pub 2025. PMID: 40193078.
34. Nastoupil, L, Andersen, C, Ayers, AA, Wang, Y, Habermann, TM, Chihara, D, Kahl, BS, Link, BK, Koff, JL, Cohen, JB, Martin, P, Lossos, IS, Stanchina, M, Haddadi, S, Casulo, C, Ayyappan, S, Lin, R, Li, Z, Larson, MC, Maurer, MJ, Huynh, L, Gao, C, Ramasubramanian, R, Duh, MS, Mutebi, A, Wang, T, Jun, M, Wang, A, Kamalakar, R, Kalsekar, A, Cerhan, JR, Flowers, CR. Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 25(4):e183-e199.e8, 2025. e-Pub 2025. PMID: 39966020.
35. Day, JR, Larson, MC, Durani, U, Koff, JL, Wang, Y, Habermann, TM, Lossos, IS, Nastoupil, L, Strouse, CS, Chihara, D, Martin, P, Leonard, JP, Cohen, JB, Kahl, BS, Ruan, J, Burack, WR, Friedberg, JW, Cerhan, JR, Flowers, CR, Link, BK, Maurer, MJ, Casulo, C. Treatment patterns and outcomes in follicular lymphoma with POD24. Blood Advances 9(5):1013-1023, 2025. e-Pub 2025. PMID: 39602301.
36. Prasad, R, Rehman, A, Rehman, L, Darbaniyan, F, Blumenberg, V, Schubert, ML, Mor, U, Zamir, E, Schmidt, S, Hayase, T, Chang, C, McDaniel, L, Flores, I, Strati, P, Nair, R, Chihara, D, Fayad, LE, Ahmed, S, Iyer, SP, Wang, ML, Jain, P, Nastoupil, L, Westin, JR, Arora, R, Turner, J, Khawaja, F, Wu, R, Dennison, JB, Menges, M, Hidalgo-Vargas, M, Reid, K, Davila, ML, Dreger, P, Korell, F, Schmitt, A, Tanner, MR, Champlin, RE, Flowers, CR, Shpall, EJ, Hanash, S, Neelapu, SS, Schmitt, M, Subklewe, M, Fahrmann, JF, Thoeringer, C, Elinav, E, Jain, MD, Hayase, E, Jenq, RR, Saini, N. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2025. e-Pub 2025. PMID: 39441941.
37. Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
38. LoRusso, P, Bradley, CJ, Cleveland, JL, Diehn, M, Figueiredo, JC, Flowers, CR, Foti, M, Hricak, H, Llanos, AA, Pignone, M, Stegmaier, K, Turaga, KK, van den Brink, MR. New Approvals Advancing Blood Cancer Medicine. Blood Cancer Discovery 6(1):5-9, 2025. e-Pub 2025. PMID: 39601608.
39. Lyu, M, Tang, X, Raso, G, Huang, M, Zeng, K, Sadeghi, T, Flowers, CR, Parmar, S. Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39975551.
40. Fang, PQ, Noticewala, SS, Wu, SY, Gunther, J, Ludmir, EB, Medeiros, LJ, Strati, P, Nair, R, Nze, CC, Nastoupil, L, Ahmed, S, Castillo, LM, Fayad, LE, Westin, J, Neelapu, SS, Flowers, CR, Huen, A, Iyer, SP, Dabaja, BS, Pinnix, CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39553398.
41. LoRusso, P, Bradley, CJ, Bunn, P, Cleveland, JL, Diehn, M, Figueiredo, JC, Flowers, CR, Foti, M, Hricak, H, Llanos, AA, Pignone, M, Stegmaier, K, Turaga, KK, van den Brink, MR, Winn, RA, Haring, RC, Gomez, SL, Mesa, RA, Ragin, CC, Bell, RA, Casillas, J, Cruz-Correa, M, Davis, M, Foti, M, Hazard-Jenkins, HW, Johnson, W, Marchand, LL, Li, CI, Nodora, J, Odunsi, A, Rodriguez, A, Schabath, MB, Springfield, SA, Studts, JL, Terry, MB, Thomas, CR, Tossas, KY, Wages, NA, Weekes, CD, Winkfield, KM, Davani, B, Davis, BC, McCarthy, J, Wallace, TA. Cancer in 2024. Cancer discovery 14(12):2324-2331, 2024. e-Pub 2024. PMID: 39618280.
42. Wang, Y, Flowers, CR, Wang, L, Huang, X, Li, Z. CASi. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38724550.
43. Abro, B, Maurer, MJ, Habermann, TM, Burack, R, Chapman, JR, Cohen, JB, Friedberg, JW, Inghirami, G, Kahl, BS, Larson, MC, Link, BK, Lossos, IS, Martin, P, McDonnell, TJ, Nastoupil, L, Riska, S, Syrbu, S, Vega Vazquez, F, Vij, K, Flowers, CR, Cerhan, JR, Jaye, DL, Feldman, AL. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma. Blood 144(19):2063-2066, 2024. e-Pub 2024. PMID: 39255410.
44. Huang, M, Ke, Z, Lyu, M, Masarova, L, Sadeghi, T, Flowers, CR, Parmar, S. CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation. iScience 27(9), 2024. e-Pub 2024. PMID: 39314243.
45. Pinnix, CC, Dabaja, BS, Gunther, J, Fang, PQ, Wu, SY, Nastoupil, L, Strati, P, Nair, R, Ahmed, S, Steiner, RE, Westin, JR, Neelapu, SS, Rodriguez, MA, Lee, HJ, Wang, L, Flowers, CR, Feng, L, Esmaeli, B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma. JAMA Oncology 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
46. Jiang, JY, Nze, CC, Guffey, D, Kim, RB, Oluyomi, AO, Rosales, O, Bandyo, R, Miller-Chism, CN, Udden, MM, Mims, MP, Ma, HY, Rivero, GA, Diamond, A, Teegavarapu, PS, Li, A, Flowers, CR. Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system. Blood Neoplasia 1(3), 2024. e-Pub 2024. PMID: 40453060.
47. Iqbal, M, Kumar, A, Dreger, P, Chavez, JC, Sauter, C, Sureda, A, Bachanova, V, Maziarz, RT, Dreyling, M, Smith, SM, Jacobson, C, Glass, B, Casulo, C, Oluwole, OO, Montoto, S, Advani, RH, Cohen, JB, Salles, G, Hamad, N, Kuruvilla, J, Kahl, BS, Shadman, M, Kanate, AS, Budde, LE, Kamdar, M, Flowers, CR, Hamadani, M, Kharfan-Dabaja, MA. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma. Transplantation and Cellular Therapy 30(9):832-843, 2024. e-Pub 2024. PMID: 38972511.
48. Khurana, A, Mwangi, R, Nastoupil, L, Reagan, P, Farooq, U, Romancik, J, McDonnell, TJ, Riska, S, Lossos, lS, Kahl, BS, Martin, P, Witzig, TE, Cerhan, JR, Flowers, CR, Nowakowski, GS, Maurer, MJ. Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL. Blood Advances 8(16):4414-4422, 2024. e-Pub 2024. PMID: 38991126.
49. Rodriguez, ER, Tonn, T, Jafry, MZ, Ahmed, S, Cuglievan, B, Livingston, JA, Flowers, CR, Aune, GJ, Albritton, KH, Roth, M, Xiao, Q, Hildebrandt, MA. Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival. JNCI Cancer Spectrum 8(4), 2024. e-Pub 2024. PMID: 39051679.
50. Gurumurthi, A, Chin, CK, Feng, L, Fowler, N, Strati, P, Hagemeister, FB, Fayad, LE, Westin, JR, Obi, C, Arafat, J, Nair, R, Steiner, RE, Neelapu, SS, Flowers, CR, Nastoupil, L. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma. EClinicalMedicine 74, 2024. e-Pub 2024. PMID: 39161543.
51. Nze, CC, Andersen, C, Ayers, AA, Westin, JR, Wang, L, Iyer, S, Ahmed, S, Pinnix, CC, Vega Vazquez, F, Nguyen, LH, McNeill, LH, Nastoupil, L, Zhang, K, Bauer, CX, Flowers, CR. Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL. Blood Advances 8(14):3825-3837, 2024. e-Pub 2024. PMID: 38607394.
52. Bock, AM, Mwangi, R, Wang, Y, Khurana, A, Maurer, MJ, Ayers, AA, Kahl, BS, Martin, P, Cohen, JB, Casulo, C, Lossos, IS, Farooq, U, Ayyappan, S, Reicks, TW, Habermann, TM, Witzig, TE, Flowers, CR, Cerhan, JR, Nastoupil, L, Nowakowski, GS. Defining primary refractory large B-cell lymphoma. Blood Advances 8(13):3402-3415, 2024. e-Pub 2024. PMID: 38669353.
53. Ma, S, La, J, Swinnerton, KN, Guffey, D, Bandyo, R, De Las Pozas, G, Hanzelka, K, Xiao, X, Rojas Hernandez, CM, Amos, CI, Chitalia, V, Ravid, K, Merriman, K, Flowers, CR, Fillmore, NR, Li, A. Thrombosis risk prediction in lymphoma patients. American journal of hematology 99(7):1230-1239, 2024. e-Pub 2024. PMID: 38654461.
54. Gunther, J, Xu, J, Bhutani, M, Strati, P, Fang, PQ, Wu, SY, Dabaja, BS, Dong, W, Bhosale, PR, Flowers, CR, Nair, R, Malpica Castillo, LE, Fayad, LE, Iyer, S, Parmer, S, Wang, ML, Lee, HJ, Samaniego, F, Westin, JR, Ahmed, S, Nze, CC, Jain, P, Neelapu, SS, Rodriguez, MA, Chihara, D, Nastoupil, L, Pinnix, CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma. The Lancet Haematology 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
55. Yuen, S, Phillips, T, Bannerji, R, Marlton, P, Gritti, G, Seymour, JF, Johnston, A, Arthur, CK, Dodero, A, Sharma, S, Hirata, J, Musick, L, Flowers, CR. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma. American journal of hematology 99(7):1281-1289, 2024. e-Pub 2024. PMID: 38700035.
56. Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica 109(7):2177-2185, 2024. e-Pub 2023. PMID: 38031804.
57. Kadia, TM, Huang, M, Pemmaraju, N, Abbas, HA, Ly, C, Masarova, L, Yilmaz, M, Mi-Ae, L, Zeng, K, Sadeghi, T, Cook, R, DiNardo, C, Daver, N, Issa, GC, Jabbour, EJ, Borthakur, G, Jain, N, Garcia-Manero, G, Parmar, S, Flowers, CR, Kantarjian, HM, Verstovsek, S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evidence 3(6), 2024. e-Pub 2024. PMID: 38804782.
58. Deng, R, Gibiansky, L, Lu, T, Flowers, CR, Sehn, L, Liu, Q, Agarwal, P, Liao, MZ, Dere, RC, Lee, C, Man, G, Hirata, J, Li, C, Miles, D. Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: Pharmacometrics and Systems Pharmacology 13(6):1055-1066, 2024. e-Pub 2024. PMID: 38622879.
59. Chi, S, Flowers, CR, Li, Z, Huang, X, Wei, P. MASH. Annals of Applied Statistics 18(2):1360-1377, 2024. e-Pub 2024.
60. Moslehi, J, Furman, RR, Tam, CS, Salem, JE, Flowers, CR, Cohen, A, Zhang, M, Zhang, J, Chen, L, Ma, H, Brown, JR. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Advances 8(10):2478-2490, 2024. e-Pub 2024. PMID: 38502198.
61. Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2023. PMID: 38031807.
62. Flowers, CR, Matasar, MJ, Herrera, AF, Hertzberg, M, Assouline, S, Demeter, J, McMillan, A, Mehta, A, Opat, SS, Trneny, M, Musick, L, Hirata, J, Yang, A, Sehn, L. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma. Haematologica 109(4):1194-1205, 2024. e-Pub 2024. PMID: 37767550.
63. Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer 130(6):876-885, 2024. e-Pub 2023. PMID: 37985359.
64. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
65. Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. Am J Hematol 99(3):408-421, 2024. e-Pub 2024. PMID: 38217361.
66. Yan F, Jiang V, Jordan A, Che Y, Liu Y, Cai Q, Xue Y, Li Y, McIntosh J, Chen Z, Vargas J, Nie L, Yao Y, Lee HH, Wang W, Bigcal JR, Badillo M, Meena J, Flowers C, Zhou J, Zhao Z, Simon LM, Wang M. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Exp Hematol Oncol 13(1):14, 2024. e-Pub 2024. PMID: 38326887.
67. Zeng, K, Ma, H, Huang, M, Lyu, M, Sadeghi, T, Flowers, CR, Parmar, S. Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes. Frontiers in Transplantation 3, 2024. e-Pub 2024. PMID: 39722683.
68. Trotman, J, Zinzani, PL, Song, YQ, Delarue, R, Kim, P, Ivanova, E, Korde, R, Mayer, J, De Oliveira, AC, Assouline, S, Flowers, CR, Barnes, G. Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy. Current Medical Research and Opinion 40(11):1863-1871, 2024. e-Pub 2024. PMID: 39376156.
69. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
70. Tavolara TE, Niazi MKK, Feldman AL, Jaye DL, Flowers C, Cooper LAD, Gurcan MN. Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning. Diagn Pathol 19(1):17, 2024. e-Pub 2024. PMID: 38243330.
71. Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma:1-5. e-Pub 2024. PMID: 38248629.
72. Singh AP, Xiao L, O'Brien BJ, Blondeau CE, Flowers CR, Bruera E, Morris VK, Shah AY. Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study. JCO Oncol Pract 20(1):OP2200782, 2024. e-Pub 2024. PMID: 37235818.
73. Leung C, Andersen CR, Wilson K, Nortje N, George M, Flowers C, Bruera E, Hui D. The impact of a multidisciplinary goals-of-care program on unplanned readmission rates at a comprehensive cancer center. Support Care Cancer 32(1):66, 2023. e-Pub 2023. PMID: 38150077.
74. Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program 2023(1):382-385, 2023. e-Pub 2023. PMID: 38066850.
75. Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzmán A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C, Lymphoma Consortium NAMC. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium. J Hematol Oncol 16(1):122, 2023. e-Pub 2023. PMID: 38104096.
76. Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
77. Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trnený M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol 41(33):101200JCO2300775, 2023. e-Pub 2023. PMID: 37506346.
78. Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, Fetooh A, Kanagal-Shamanna R, Vega F, Bagaev A, Fowler N, Flowers CR, Wang M. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J 13(1):156, 2023. e-Pub 2023. PMID: 37821434.
79. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
80. Li A, May SB, La J, Martens KL, Amos CI, Flowers CR, Do NV, Brophy MT, Chitalia V, Ravid K, Gaziano JM, Fillmore NR. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol 98(8):1214-1222, 2023. e-Pub 2023. PMID: 37161855.
81. Li A, De Las Pozas G, Andersen CR, Nze CC, Toale KM, Milner EM, Fillmore NR, Chiao EY, Rojas Hernandez C, Kroll MH, Merriman KW, Flowers CR. External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. Am J Hematol 98(7):1052-1057, 2023. e-Pub 2023. PMID: 37067102.
82. Gladstone DE, D'Alessio F, Howard C, Lyu MA, Mock JR, Gibbs KW, Abrams D, Huang M, Zeng K, Herlihy JP, Castillo ST, Bassett R, Sadeghi T, Parmar S, Flowers CR, Mukherjee S, Schoenfeld D, Thall PF, Slutsky AS. Randomized, Double Blinded, Placebo Controlled Trial of Allogeneic Cord Blood T-Regulatory Cell for Treatment of COVID-19 ARDS. Blood Adv 7(13):3075-3079, 2023. e-Pub 2023. PMID: 36961352.
83. Zeng K, Huang M, Lyu MA, Khoury JD, Ahmed S, Patel KK, Dropulic B, Reese-Koc J, Caimi PF, Sadeghi T, Lima M, Flowers CR, Parmar S. Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells 12(14), 2023. e-Pub 2023. PMID: 37508543.
84. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 41(16):JCO2300294, 2023. e-Pub 2023. PMID: 37075273.
85. Li A, La J, May SB, Guffey D, da Costa WL, Amos CI, Bandyo R, Milner EM, Kurian KM, Chen DCR, Do NV, Granada C, Riaz N, Brophy MT, Chitalia V, Gaziano JM, Garcia DA, Carrier M, Flowers CR, Zakai NA, Fillmore NR. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol 41(16):2926-2938, 2023. e-Pub 2023. PMID: 36626707.
86. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv 7(11):2287-2296, 2023. e-Pub 2023. PMID: 36516079.
87. Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman JR, Strouse C, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 141(15):1888-1893, 2023. e-Pub 2023. PMID: 36735908.
88. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
89. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
90. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2023. PMID: 36375046.
91. Hui, D, Ahmed, S, Nortje, N, George, MC, Andersen, C, Wilson, K, Urbauer, D, Flowers, CR, Bruera, E. Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies. Cancers 15(5), 2023. e-Pub 2023. PMID: 36900298.
92. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
93. Lasater EA, Amin DN, Bannerji R, Mali RS, Barrett K, Rys RN, Oeh J, Lin E, Sterne-Weiler T, Ingalla ER, Go M, Yu SF, Krem MM, Arthur C, Hahn U, Johnston A, Karur V, Khan N, Marlton P, Phillips T, Gritti G, Seymour JF, Tani M, Yuen S, Martin S, Chang MT, Rose CM, Pham VC, Polson AG, Chang Y, Wever C, Johnson NA, Jiang Y, Hirata J, Sampath D, Musick L, Flowers CR, Wertz IE. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study. Am J Hematol 98(3):449-463, 2023. e-Pub 2023. PMID: 36594167.
94. Lyu MA, Huang M, Zeng K, Li L, Khoury JD, Nishimoto M, Ma H, Sadeghi T, Mukherjee S, Slutsky AS, Flowers CR, Parmar S. Allogeneic cord blood regulatory T cells can resolve lung inflammation. Cytotherapy 25(3):245-253, 2023. e-Pub 2023. PMID: 36437190.
95. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):745-755, 2023. e-Pub 2023. PMID: 35952327.
96. Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, Che Y, Chen Z, Vargas J, Badillo M, Bigcal JN, Lee HH, Wang W, Yao Y, Nie L, Flowers CR, Wang M. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest 133(3), 2023. e-Pub 2023. PMID: 36719376.
97. Hui D, Nortje N, George M, Wilson K, Urbauer DL, Lenz CA, Wallace SK, Andersen CR, Mendoza T, Haque S, Ahmed S, Delgado-Guay M, Dalal S, Rathi N, Reddy A, McQuade J, Flowers C, Pisters P, Aloia T, Bruera E. Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis. J Clin Oncol 41(3):JCO2200849, 2023. e-Pub 2022. PMID: 36201711.
98. Lyu, M, Tang, X, Khoury, J, Raso, G, Huang, M, Zeng, K, Nishimoto, M, Ma, H, Sadeghi, T, Flowers, CR, Parmar, S. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. Frontiers in immunology 14, 2023. e-Pub 2023. PMID: 37736101.
99. McCurry D, Flowers CR, Bermack C. Immune-based therapies in Diffuse Large B-Cell Lymphoma. Expert Opin Investig Drugs 32(6):479-493, 2023. e-Pub 2023. PMID: 37394970.
100. Lipscomb J, Switchenko JM, Flowers CR, Gillespie TW, Wortley PM, Bayakly AR, Almon L, Ward KC. Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia. Leuk Lymphoma 64(1):1-10, 2023. e-Pub 2022. PMID: 36308021.
101. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
102. Jiang, C, Hao, D, Jain, P, Li, Y, Cai, Q, Yao, Y, Nie, L, Liu, Y, Jin, J, Wang, W, Lee, H, Che, Y, Dai, E, Han, G, Wang, R, Rai, K, Futreal, A, Flowers, CR, Wang, L, Wang, L. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Molecular cancer 21(1), 2022. e-Pub 2022. PMID: 36163179.
103. Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. Ann Appl Stat 16(4):2481-2504, 2022. e-Pub 2022. PMID: 36329718.
104. Flowers CR, Odejide OO. Sequencing therapy in relapsed DLBCL. Hematology Am Soc Hematol Educ Program 2022(1):146-154, 2022. e-Pub 2022. PMID: 36485076.
105. Romancik JT, Chen Z, Allen PB, Waller EK, Valla K, Colbert A, Rosand C, Palmer AF, Flowers CR, Cohen JB. Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial. Clin Lymphoma Myeloma Leuk 22(12):e1084-e1091, 2022. e-Pub 2022. PMID: 36180329.
106. Fahrmann, JF, Saini, N, Chang, C, Irajizad, E, Strati, P, Nair, R, Fayad, LE, Ahmed, S, Lee, HJ, Iyer, SP, Steiner, RE, Vykoukal, JV, Wu, R, Dennison, JB, Nastoupil, L, Jain, P, Wang, L, Green, M, Westin, JR, Blumenberg, V, Davila, ML, Champlin, RE, Shpall, E, Kebriaei, P, Flowers, CR, Jain, MD, Jenq, RR, Thoeringer, C, Subklewe, M, Neelapu, SS, Hanash, S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports Medicine 3(11), 2022. e-Pub 2022. PMID: 36384092.
107. Dixon, JG, Çağlayan, Ç, Chihara, D, Nielsen, TG, Dimier, N, Zheng, J, Wall, A, Salles, G, Morschhauser, F, Marcus, RE, Herold, M, Kimby, E, Blum, KA, Ghielmini, M, Shi, Q, Flowers, CR. Factors Affecting the Clinical Course of Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 22(11):e1009-e1018, 2022. e-Pub 2022. PMID: 36045021.
108. Strati, P, Jallouk, AP, Sun, R, Choi, J, Das, K, Cherng, HJ, Ahmed, S, Lee, HJ, Iyer, SP, Nair, R, Nastoupil, L, Steiner, RE, Huff, C, Yu, Y, Mistry, HE, Pulsifer, B, Noorani, M, Saini, N, Shpall, E, Kebriaei, P, Flowers, CR, Westin, JR, Hildebrandt, MA, Neelapu, SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
109. Flowers, CR, Tilly, H, Morschhauser, F, Sehn, L, Friedberg, JW, Trneny, M, Sharman, JP, Herbaux, C, Burke, JM, Matasar, MJ, Rai, S, Izutsu, K, Mehta-Shah, N, Oberic, L, Chauchet, A, Jurczak, W, Song, YQ, Greil, R, Mykhalska, L, Bergua-Burgués, JM, Cheung, MC, Pinto, A, Shin, HJ, Hapgood, G, Munhoz, E, Abrisqueta, P, Gau, JP, Hirata, J, Jiang, Y, Yan, M, Lee, C, Salles, G. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia 22:S358-S359, 2022. e-Pub 2022. PMID: 36164048.
110. Flowers, CR, Burke, JM, Vukcevic, M, Snodgrass, S, Saverno, K, Lumiqued, MA, Abdulhaq, H, Brem, E, Evens, AM, Farooq, U, Porcu, P, Shadman, M. ABCL-051 realMIND. Clinical Lymphoma, Myeloma and Leukemia 22:S355-S356, 2022. e-Pub 2022. PMID: 36164044.
111. Xie C, Li R, Huang X, Chihara D, Flowers CR. The Impact of Sequence of Therapy for Older Patients With Follicular Lymphoma: SEER-Medicare Analysis. Clin Lymphoma Myeloma Leuk 22(10):e938-e946, 2022. e-Pub 2022. PMID: 35871217.
112. Chang, A, Sholukh, AM, Wieland, A, Jaye, DL, Carrington, M, Huang, ML, Xie, H, Jerome, KR, Roychoudhury, P, Greninger, AL, Koff, JL, Cohen, JB, Koelle, DM, Corey, L, Flowers, CR, Ahmed, R. Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia. Journal of Clinical Investigation 132(18), 2022. e-Pub 2022. PMID: 35862190.
113. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
114. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
115. Wang Y, Flowers CR, Li Z, Huang X. CondiS web app: imputation of censored lifetimes for machine learning-based survival analysis. Bioinformatics 38(17):4252-4254, 2022. e-Pub 2022. PMID: 35801895.
116. Chihara D, Lin R, Flowers CR, Finnigan SR, Cordes LM, Fukuda Y, Huang EP, Rubinstein LV, Nastoupil LJ, Ivy SP, Doroshow JH, Takebe N. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet 400(10351):512-521, 2022. e-Pub 2022. PMID: 35964611.
117. Luan D, Fatola T, Toure A, Flowers CR, Link B, Friedberg JW, Cohen JB, Kahl B, Lossos IS, Nastoupil L, Maurer MJ, Cerhan JR, Martin P. Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis. Blood Adv 6(15):4413-4423, 2022. e-Pub 2022. PMID: 35793440.
118. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
119. da Costa WL, Guffey D, Oluyomi A, Bandyo R, Rosales O, Wallace CD, Granada C, Riaz N, Fitzgerald M, Garcia DA, Carrier M, Amos CI, Flowers CR, Li A. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. Am J Hematol 97(8):1044-1054, 2022. e-Pub 2022. PMID: 35638475.
120. Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, Rice EJ, Muley A, Camarillo JM, Arivalagan J, Li Z, Flowers CR, Kelleher NL, Danko CG, Imielinski M, Dave SS, Armstrong SA, Mason CE, Melnick AM. SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. Cancer Discov 12(7):1782-1803, 2022. e-Pub 2022. PMID: 35443279.
121. Wang Y, Flowers CR, Li Z, Huang X. CondiS: A conditional survival distribution-based method for censored data imputation overcoming the hurdle in machine learning-based survival analysis. J Biomed Inform 131:104117, 2022. e-Pub 2022. PMID: 35690348.
122. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
123. Chihara D, Huang EP, Finnigan SR, Cordes LM, Skorupan N, Fukuda Y, Rubinstein LV, Ivy SP, Doroshow JH, Nastoupil LJ, Flowers CR, Takebe N. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol 40(17):1949-1957, 2022. e-Pub 2022. PMID: 35263120.
124. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
125. Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35230977.
126. Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol 9(4):e289-e300, 2022. e-Pub 2022. PMID: 35358443.
127. Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma 63(4):1-13, 2022. e-Pub 2022. PMID: 34865586.
128. Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials. Blood 139(11):1684-1693, 2022. e-Pub 2022. PMID: 34614146.
129. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
130. Wang SS, Vajdic CM, Linet MS, Slager SL, Voutsinas J, Nieters A, Casabonne D, Cerhan JR, Cozen W, Alarcon G, Martínez-Maza O, Brown EE, Bracci PM, Turner J, Hjalgrim H, Bhatti P, Zhang Y, Birmann BM, Flowers CR, Paltiel O, Holly EA, Kane E, Weisenburger DD, Maynadié M, Cocco P, Foretova L, Breen EC, Lan Q, Brooks-Wilson A, De Roos AJ, Smith MT, Roman E, Boffetta P, Kricker A, Zheng T, Skibola CF, Clavel J, Monnereau A, Chanock SJ, Rothman N, Benavente Y, Hartge P, Smedby KE. B-cell non-Hodgkin lymphoma (NHL) subtype risk associated with autoimmune conditions and polygenic risk scores (PRS). Cancer Epidemiol Biomarkers Prev. e-Pub 2022. PMID: 35244686.
131. Harkins RA, Patel S, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR. Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey. Blood Adv. e-Pub 2022. PMID: 35100356.
132. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trnený M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351-363, 2022. e-Pub 2022. PMID: 34904799.
133. Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, Gupta VA, Chandrakasan S, Zoine JT, Fedanov A, Raikar SS, Koff JL, Flowers CR, Coma S, Pachter JA, Ravindranathan S, Spencer HT, Shanmugam M, Waller EK. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood 139(4):523-537, 2022. e-Pub 2022. PMID: 35084470.
134. Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, Kim TM, McMillan A, Ozcan M, Safar V, Salles G, Ku G, Hirata J, Chang YM, Musick L, Matasar MJ. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533-543, 2022. e-Pub 2022. PMID: 34749395.
135. Al Zaki A, Feng L, Watson G, Ahmed S, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv. e-Pub 2022. PMID: 35015825.
136. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):202-212, 2022. e-Pub 2022. PMID: 34797699.
137. Cherng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 63(1):74-83, 2022. e-Pub 2022. PMID: 34435552.
138. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv 5(23):5179-5189, 2021. e-Pub 2021. PMID: 34516611.
139. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era. Am J Hematol 96(11):1374-1384, 2021. e-Pub 2021. PMID: 34324220.
140. Chihara D, Larson MC, Robinson DP, Thompson CA, Maurer MJ, Casulo C, Pophali P, Link BK, Habermann TM, Feldman AL, Flowers CR, Cerhan JR, Morton LM. Body mass index and survival of patients with lymphoma. Leuk Lymphoma 62(11):1-8, 2021. e-Pub 2021. PMID: 34121594.
141. Chrit FE, Raj A, Young KM, Stone NE, Shankles PG, Lokireddy K, Flowers C, Waller EK, Alexeev A, Sulchek T. Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. ACS Sens 6(10):3789-3799, 2021. e-Pub 2021. PMID: 34546721.
142. Strati P, De Vos S, Ruan J, Maddocks KJ, Flowers CR, Rule S, Patel P, Xu Y, Wei H, Frigault MM, Calvo R, Dyer MJS. Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study. Haematologica 106(10):2774-2778, 2021. e-Pub 2021. PMID: 34233448.
143. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):1-8, 2021. e-Pub 2021. PMID: 33942701.
144. Goldman ML, Mao JJ, Strouse CS, Chen W, Rupji M, Chen Z, Maurer MJ, Calzada O, Churnetski M, Flowers CR, Cerhan JR, Link BK, Thompson CA, Cohen JB. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer 127(18):3390-3402, 2021. e-Pub 2021. PMID: 34157780.
145. Chihara D, Dores GM, Flowers CR, Morton LM. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138(9):785-789, 2021. e-Pub 2021. PMID: 33822002.
146. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival. Eur J Haematol 107(3):301-310, 2021. e-Pub 2021. PMID: 33973276.
147. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
148. Chang A, Ellingson MK, Flowers CR, Bednarczyk RA. Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey. Open Forum Infect Dis 8(7):ofab198, 2021. e-Pub 2021. PMID: 34322565.
149. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
150. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
151. Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
152. Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jørgensen, JM, Poeschel, V, Nowakowski, GS, Seymour, JF, Merli, F, Haioun, C, Ghesquières, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, Habermann, TM. Relapsed / Refractory International Prognostic Index (R/R-IPI). American journal of hematology 96(5):599-605, 2021. e-Pub 2021. PMID: 33661547.
153. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
154. Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leuk Lymphoma 62(5):1077-1087, 2021. e-Pub 2021. PMID: 33300385.
155. Ballas LK, Metzger ML, Milgrom SA, Advani R, Bakst RL, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Constine LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leuk Lymphoma 62(5):1057-1065, 2021. e-Pub 2021. PMID: 33274673.
156. Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv 5(6):1737-1745, 2021. e-Pub 2021. PMID: 33749762.
157. Smith-Graziani D, Flowers CR. Understanding and Addressing Disparities in Patients with Hematologic Malignancies: Approaches for Clinicians. Am Soc Clin Oncol Educ Book 41:1-7, 2021. e-Pub 2021. PMID: 33793311.
158. Dance KV, Imbody CB, Chen L, McNeill L, Payne JB, Flowers CR. Perceptions of clinical care and research among African American patients with lymphoma. Leuk Lymphoma:1-13. e-Pub 2021. PMID: 33645400.
159. Merdan S, Subramanian K, Ayer T, Van Weyenbergh J, Chang A, Koff JL, Flowers C. Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. Blood Cancer J 11(1):2, 2021. e-Pub 2021. PMID: 33414466.
160. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192(2):e38-e42, 2021. e-Pub 2021. PMID: 33152104.
161. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma 61(12):2985-2989, 2020. e-Pub 2020. PMID: 32628087.
162. Harkins RA, Flowers CR. How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. Leuk Lymphoma 61(14):1-4, 2020. e-Pub 2020. PMID: 33143518.
163. Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, Morschhauser F, Collins GP, Ma S, Peles S, Smith SD, Barrientos JC, Chong E, Wu S, Cheung LW, Kwei K, Hauns B, Arango-Hisijara I, Chen R. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 4(22):5773-5784, 2020. e-Pub 2020. PMID: 33227125.
164. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
165. Kudelka MR, Switchenko JM, Lechowicz MJ, Esiashvili N, Flowers CR, Khan MK, Allen PB. Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival with Ultraviolet Therapy. Clin Lymphoma Myeloma Leuk 20(11):757-767.e3, 2020. e-Pub 2020. PMID: 32703750.
166. Payne JB, Flowers CR, Allen PB. Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women with Cancer. Oncology (Williston Park) 34(11):494-499, 2020. e-Pub 2020. PMID: 33206987.
167. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC, Shih YT, Walter LC, Kim JJ, Andrews KS, DeSantis CE, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC, Smith RA. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 70(5):321-346, 2020. e-Pub 2020. PMID: 32729638.
168. Lee MJ, Koff JL, Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave SS, Flowers CR. Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-Cell lymphoma. Cancer 126(15):3493-3503, 2020. e-Pub 2020. PMID: 32469082.
169. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
170. Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Glob Oncol 6:1124-1133, 2020. e-Pub 2020. PMID: 32692628.
171. Flowers CR, Leonard JP, Fowler NH. Lenalidomide in follicular lymphoma. Blood 135(24):2133-2136, 2020. e-Pub 2020. PMID: 32236519.
172. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
173. Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematol 7(6):e490-e497, 2020. e-Pub 2020. PMID: 32470440.
174. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
175. Williams S, Ayers AA, Hildebrandt MT, McNeill LH, Flowers CR. Strategies for Overcoming Disparities for Patients with Hematologic Malignancies and for Improving Enrollment on Clinical Trials. Oncology (Williston Park) 34(6):216-223, 2020. e-Pub 2020. PMID: 32609869.
176. Clough L, Bayakly AR, Ward KC, Khan MK, Chen SC, Lechowicz MJ, Flowers CR, Allen PB, Switchenko JM. Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. Cancer 126(8):1700-1707, 2020. e-Pub 2020. PMID: 31943154.
177. Mato A, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Swern AS, Sullivan K, Flick ED, Gressett Ussery SM, Gharibo M, Kiselev P, Sharman JP. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv 4(7):1407-1418, 2020. e-Pub 2020. PMID: 32271900.
178. Patel SP, Harkins RA, Lee MJ, Flowers CR, Koff JL. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 20(4):234-243.e10, 2020. e-Pub 2020. PMID: 32063526.
179. Lipscomb J, Switchenko JM, Flowers CR, Gillespie TW, Wortley PM, Bayakly AR, Almon L, Fernando R, Ward KC. Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia. Leuk Lymphoma 61(4):1-9, 2020. e-Pub 2020. PMID: 31852329.
180. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
181. Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer 126(6):1235-1242, 2020. e-Pub 2020. PMID: 31821549.
182. Jiang C, Syed YA, Burdette EB, Jaye DL, Flowers CR, Khan MK. Retroperitoneal Follicular Dendritic Cell Sarcoma: A Case Report. Adv Radiat Oncol 5(2):297-300, 2020. e-Pub 2020. PMID: 32280831.
183. Allen PB, Ayers A, Behera M, Evens AM, Flowers C. A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. Leuk Lymphoma:1-10. e-Pub 2020. PMID: 32102579.
184. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 38(5):496-520, 2020. e-Pub 2020. PMID: 31381464.
185. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 38(2):155-165, 2020. e-Pub 2020. PMID: 31693429.
186. Chen L, Payne JB, Dance KV, Imbody CB, Ho CD, Ayers AA, Flowers CR. Priorities for Rural Lymphoma Survivors: A Qualitative Study. Clin Lymphoma Myeloma Leuk 20(1):47-52.e3, 2020. e-Pub 2020. PMID: 31708453.
187. Goldstein JS, Switchenko JM, Behera M, Flowers CR, Koff JL. Insurance status impacts overall survival in Burkitt lymphoma. Leuk Lymphoma 60(13):1-10, 2019. e-Pub 2019. PMID: 31274033.
188. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 134(21):1811-1820, 2019. e-Pub 2019. PMID: 31558467.
189. Payne JB, Dance KV, Farone M, Phan A, Ho CD, Gutierrez M, Chen L, Flowers CR. Patient and caregiver perceptions of lymphoma care and research opportunities: A qualitative study. Cancer 125(22):4096-4104, 2019. e-Pub 2019. PMID: 31355929.
190. Teras LR, Diver WR, Deubler EL, Krewski D, Flowers CR, Switchenko JM, Gapstur SM. Residential ambient benzene exposure in the United States and subsequent risk of hematologic malignancies. Int J Cancer 145(10):2647-2660, 2019. e-Pub 2019. PMID: 30737780.
191. Blanquicett C, Cohen JB, Flowers C, Johnson T. The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient. Oncology (Williston Park) 33(11), 2019. e-Pub 2019. PMID: 31769862.
192. Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein JS, Merdan S, Flowers CR, Koff JL. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Rev Hematol 12(11):959-973, 2019. e-Pub 2019. PMID: 31513757.
193. Ayers AA, Lyu L, Dance K, Ward KC, Flowers CR, Koff JL, McCullough LE. Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region. Clin Lymphoma Myeloma Leuk 19(11):699-708.e5, 2019. e-Pub 2019. PMID: 31494062.
194. Harkins RA, Patel SP, Flowers CR. Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. Cancer J 25(6):418-427, 2019. e-Pub 2019. PMID: 31764123.
195. Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ. Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs. Leuk Lymphoma 60(10):2356-2364, 2019. e-Pub 2019. PMID: 31164024.
196. Islam P, Goldstein J, Flowers CR. PET-derived tumor metrics predict DLBCL response and progression-free survival. Leuk Lymphoma 60(8):1965-1971, 2019. e-Pub 2019. PMID: 30714446.
197. Ritter AJ, Goldstein JS, Ayers AA, Flowers CR. Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. Leuk Lymphoma 60(7):1656-1667, 2019. e-Pub 2019. PMID: 30632824.
198. Ç Ç, Goldstein JS, Ayer T, Rai A, Flowers CR. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. Cancer 125(11):1837-1847, 2019. e-Pub 2019. PMID: 30707765.
199. Shah NN, Xi Y, Liu Y, Koff JL, Flowers CR, Behera M, Cohen JB. Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 19(6):e312-e320, 2019. e-Pub 2019. PMID: 31029647.
200. Ç Ç, Terawaki H, Ayer T, Goldstein JS, Rai A, Chen Q, Flowers C. Assessing the Effectiveness of Treatment Sequences for Older Patients with High-risk Follicular Lymphoma With a Multistate Model. Clin Lymphoma Myeloma Leuk 19(5):300-309.e5, 2019. e-Pub 2019. PMID: 30686772.
201. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma 60(4):940-946, 2019. e-Pub 2019. PMID: 30277110.
202. Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma 60(4):894-903, 2019. e-Pub 2019. PMID: 30277102.
203. Chang A, Payne JB, Allen PB, Koff JL, Ahmed R, Flowers CR, Bednarczyk RA. Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma. Clin Lymphoma Myeloma Leuk 19(4):239-243, 2019. e-Pub 2019. PMID: 30686773.
204. Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR. Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. Leuk Lymphoma:1-9. e-Pub 2019. PMID: 30848966.
205. Hall KH, Valla K, Flowers CR, Cohen JB. Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-cell Lymphoma at an Academic Healthcare System. Clin Lymphoma Myeloma Leuk 19(2):89-94, 2019. e-Pub 2019. PMID: 30528416.
206. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. e-Pub 2019. PMID: 30709431.
207. Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW. Second line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 184(4):660-663, 2019. e-Pub 2019. PMID: 29611177.
208. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma 59(12):2862-2870, 2018. e-Pub 2018. PMID: 29912594.
209. Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA. The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93(12):1543-1550, 2018. e-Pub 2018. PMID: 30230581.
210. Blum KA, Keller FG, Castellino S, Phan A, Flowers CR. Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. Br J Haematol 183(3):385-399, 2018. e-Pub 2018. PMID: 30095154.
211. Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study. Leuk Lymphoma 59(10):2327-2335, 2018. e-Pub 2018. PMID: 29415595.
212. Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR. Disparities in survival by insurance status in follicular lymphoma. Blood 132(11):1159-1166, 2018. e-Pub 2018. PMID: 30042094.
213. de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol 29(9):1932-1938, 2018. e-Pub 2018. PMID: 30060083.
214. Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). J Clin Oncol 36(25):2593-2602, 2018. e-Pub 2018. PMID: 29975624.
215. Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(9):569-575.e1, 2018. e-Pub 2018. PMID: 30122201.
216. Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29(8):1822-1827, 2018. e-Pub 2018. PMID: 29897404.
217. Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR. History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8(8):73, 2018. e-Pub 2018. PMID: 30069001.
218. Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78(14):4086-4096, 2018. e-Pub 2018. PMID: 29735552.
219. Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma 59(7):1700-1709, 2018. e-Pub 2018. PMID: 29065744.
220. Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin 68(4):250-281, 2018. e-Pub 2018. PMID: 29846947.
221. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124(11):2306-2315, 2018. e-Pub 2018. PMID: 29579328.
222. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 24(6):1163-1171, 2018. e-Pub 2018. PMID: 29242111.
223. Keegan THM, Li Q, Steele A, Alvarez EM, Brunson A, Flowers CR, Glaser SL, Wun T. Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes Control 29(6):551-561, 2018. e-Pub 2018. PMID: 29654427.
224. Feldman AL, Flowers CR. Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database. Br J Haematol 181(6):721-722, 2018. e-Pub 2018. PMID: 29676455.
225. Guidot DM, Switchenko JM, Nastoupil LJ, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59(4):888-895, 2018. e-Pub 2018. PMID: 28797213.
226. Petersen CT, Hassan M, Morris AB, Jeffery J, Lee K, Jagirdar N, Staton AD, Raikar SS, Spencer HT, Sulchek T, Flowers CR, Waller EK. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. Blood Adv 2(3):210-223, 2018. e-Pub 2018. PMID: 29386194.
227. Koff JL, Rai A, Flowers CR. Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort. Clin Lymphoma Myeloma Leuk 18(2):e115-e121, 2018. e-Pub 2018. PMID: 29273217.
228. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk 18(2):114-124.e2, 2018. e-Pub 2018. PMID: 29352719.
229. Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv 1(25):2433-2443, 2017. e-Pub 2017. PMID: 29296893.
230. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer 123(22):4411-4418, 2017. e-Pub 2017. PMID: 28749548.
231. Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 35(31):3538-3546, 2017. e-Pub 2017. PMID: 28862883.
232. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 171(2):481-494.e15, 2017. e-Pub 2017. PMID: 28985567.
233. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED. Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol 35(26):3075-3082, 2017. e-Pub 2017. PMID: 28737975.
234. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED. Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Cancer Res 77(17):4548-4555, 2017. e-Pub 2017. PMID: 28739629.
235. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED. Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. CA Cancer J Clin 67(5):353-361, 2017. e-Pub 2017. PMID: 28738442.
236. Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. Leuk Lymphoma 58(9):1-2, 2017. e-Pub 2017. PMID: 28278718.
237. Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene 36(29):4224-4232, 2017. e-Pub 2017. PMID: 28368397.
238. Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol 178(1):72-80, 2017. e-Pub 2017. PMID: 28542862.
239. Rai A, Nastoupil LJ, Williams JN, Lipscomb J, Ward KC, Howard DH, Lee D, Flowers CR. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. Leuk Lymphoma 58(7):1570-1580, 2017. e-Pub 2017. PMID: 27830968.
240. Hamilton BK, Rybicki L, Abounader D, Adekola K, Advani A, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers CR, Ganguly S, Jagasia M, Kennedy VE, Kim DDH, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner SB, Perales MA, Majhail NS. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(7):1117-1121, 2017. e-Pub 2017. PMID: 28396160.
241. Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 129(22):3037-3039, 2017. e-Pub 2017. PMID: 28325864.
242. Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, Langston A, Nooka AK. Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infect Control Hosp Epidemiol 38(6):651-657, 2017. e-Pub 2017. PMID: 28330512.
243. Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist 22(6):694-699, 2017. e-Pub 2017. PMID: 28592621.
244. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129(16):2224-2232, 2017. e-Pub 2017. PMID: 28167659.
245. Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol 35(11):1194-1202, 2017. e-Pub 2017. PMID: 28221865.
246. McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS. The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discov 7(4):369-379, 2017. e-Pub 2017. PMID: 28122867.
247. Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica 102(4):e156-e159, 2017. e-Pub 2017. PMID: 27979923.
248. Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma 58(4):809-815, 2017. e-Pub 2017. PMID: 27562750.
249. Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick ED, Kiselev P, Sharman JP. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer 17(1):198, 2017. e-Pub 2017. PMID: 28302090.
250. Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, Flowers CR. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. Cancer Epidemiol Biomarkers Prev 26(3):303-311, 2017. e-Pub 2017. PMID: 27756777.
251. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol 35(5):552-560, 2017. e-Pub 2017. PMID: 28029309.
252. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol 92(2):161-170, 2017. e-Pub 2017. PMID: 27880984.
253. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol 35(2):166-174, 2017. e-Pub 2017. PMID: 27870563.
254. Danish HH, Liu S, Jhaveri J, Flowers CR, Lechowicz MJ, Esiashvili N, Khan MK. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome. Leuk Lymphoma 57(12):2813-2819, 2016. e-Pub 2016. PMID: 27104864.
255. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol 175(5):892-903, 2016. e-Pub 2016. PMID: 27861736.
256. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443-459, 2016. e-Pub 2016. PMID: 27618563.
257. Bulka C, Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Ward KC, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR. Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence. South Med J 109(10):606-614, 2016. e-Pub 2016. PMID: 27706495.
258. Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer 122(15):2356-63, 2016. e-Pub 2016. PMID: 27153197.
259. DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F, Flowers CR, Kota VK, Al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ. Does Post-Transplant Maintenance Therapy with Tyrosine Kinase Inhibitors Improve Outcomes of Patients with High-Risk Philadelphia Chromosome-Positive Leukemia?. Clin Lymphoma Myeloma Leuk 16(8):466-471.e1, 2016. e-Pub 2016. PMID: 27297665.
260. Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol 91(8):770-5, 2016. e-Pub 2016. PMID: 27124800.
261. Cassidy RJ, Jegadeesh N, Switchenko J, Danish H, Esiashvili N, Flowers CR, Khan MK. The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 57(8):1876-82, 2016. e-Pub 2016. PMID: 26759182.
262. Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant 22(7):1197-1205, 2016. e-Pub 2016. PMID: 27040394.
263. Moss E, Goldstein DA, Bradley KT, Flowers CR, Murphy DA. Successful Robotic Excision and Early Chemotherapy for Primary Cardiac Lymphoma. Ann Thorac Surg 102(1):304-5, 2016. e-Pub 2016. PMID: 27343500.
264. Danish HH, Heumann TR, Bradley KT, Switchenko J, Esiashvili N, Lechowicz MJ, Flowers CR, Khan MK. CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation. Dermatol Ther (Heidelb) 6(2):251-63, 2016. e-Pub 2016. PMID: 27085537.
265. Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol 33(5):48, 2016. e-Pub 2016. PMID: 27067436.
266. Deng J, Pennati A, Cohen JB, Wu Y, Ng S, Wu JH, Flowers CR, Galipeau J. GIFT4 fusokine converts leukemic B cells into immune helper cells. J Transl Med 14(1):106, 2016. e-Pub 2016. PMID: 27118475.
267. Machiela MJ, Lan Q, Slager SL, Vermeulen RC, Teras LR, Camp NJ, Cerhan JR, Spinelli JJ, Wang SS, Nieters A, Vijai J, Yeager M, Wang Z, Ghesquières H, McKay J, Conde L, de Bakker PI, Cox DG, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Giles GG, Melbye M, Gu J, Jackson RD, Kane E, Purdue MP, Vajdic CM, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Roos G, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Boeing H, Tjønneland A, Angelucci E, Di Lollo S, Rais M, De Vivo I, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Liang L, Park JH, Chung CC, Weisenburger DD, Fraumeni JF, Salles G, Glenn M, Cannon-Albright L, Curtin K, Wu X, Smedby KE, de Sanjose S, Skibola CF, Berndt SI, Birmann BM, Chanock SJ, Rothman N. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum Mol Genet 25(8):1663-76, 2016. e-Pub 2016. PMID: 27008888.
268. Switchenko JM, Bulka C, Ward K, Koff JL, Bayakly AR, Ryan PB, Waller LA, Flowers CR. Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma. Cancer Epidemiol 41:139-51, 2016. e-Pub 2016. PMID: 26949112.
269. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 172(5):724-34, 2016. e-Pub 2016. PMID: 26729445.
270. Keegan TH, DeRouen MC, Parsons HM, Clarke CA, Goldberg D, Flowers CR, Glaser SL. Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study. Cancer Epidemiol Biomarkers Prev 25(2):264-73, 2016. e-Pub 2016. PMID: 26826029.
271. Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer 54:11-17, 2016. e-Pub 2016. PMID: 26707592.
272. Yun HD, Dossul T, Bernal-Mizrachi L, Switchenko J, Ndibe C, Ibraheem A, Dixon MD, Langston AA, Nooka AK, Flowers CR, Pentz RD, Waller EK. Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. J Stem Cell Res Ther 6, 2016. e-Pub 2016. PMID: 28966870.
273. Chen Q, Ayer T, Nastoupil LJ, Koff JL, Staton AD, Chhatwal J, Flowers CR. Population-specific prognostic models are needed to stratify outcomes for African Americans with diffuse large B-cell lymphoma. Leuk Lymphoma 57(4):842-51, 2016. e-Pub 2016. PMID: 26415108.
274. Hung OY, Brown JR, Dai T, Easley KA, Flowers CR, Parashar S. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. BMJ Open 5(10):e008350, 2015. e-Pub 2015. PMID: 26443656.
275. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R, Society AC. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society. JAMA 314(15):1599-614, 2015. e-Pub 2015. PMID: 26501536.
276. Jagirdar N, Harvey RD, Nooka A, Flowers C, Kaufman J, Lonial S, Lechowicz MJ, Langston A, Lipscomb C, Gaylor C, Waller EK. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion 55(10):2351-7, 2015. e-Pub 2015. PMID: 26331348.
277. Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126(7):851-7, 2015. e-Pub 2015. PMID: 26105149.
278. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516-22, 2015. e-Pub 2015. PMID: 26124482.
279. Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33(21):2399-404, 2015. e-Pub 2015. PMID: 26077240.
280. Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol 170(1):85-95, 2015. e-Pub 2015. PMID: 25851937.
281. Williams JN, Rai A, Lipscomb J, Koff JL, Nastoupil LJ, Flowers CR. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer 121(11):1800-8, 2015. e-Pub 2015. PMID: 25675909.
282. Heumann TR, Esiashvili N, Parker S, Switchenko JM, Dhabbaan A, Goodman M, Lechowicz MJ, Flowers CR, Khan MK. Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique. Int J Radiat Oncol Biol Phys 92(1):183-91, 2015. e-Pub 2015. PMID: 25670538.
283. Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma 56(5):1295-302, 2015. e-Pub 2015. PMID: 25263322.
284. Jegadeesh N, Rajpara R, Esiashvili N, Shi Z, Liu Y, Okwan-Duodu D, Flowers CR, Khan MK. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Int J Radiat Oncol Biol Phys 92(1):107-12, 2015. e-Pub 2015. PMID: 25863758.
285. Davis CC, Cohen JB, Shah KS, Hutcherson DA, Surati MJ, Valla K, Panjic EH, Handler CE, Switchenko JM, Flowers CR. Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 15(5):270-7, 2015. e-Pub 2015. PMID: 25704479.
286. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 33(10):1112-8, 2015. e-Pub 2015. PMID: 25691669.
287. Chen Q, Ayer T, Nastoupil LJ, Rose AC, Flowers CR. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. Value Health 18(2):189-97, 2015. e-Pub 2015. PMID: 25773554.
288. Flowers CR, Cohen JB, Khan MK. Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 56(3):557-8, 2015. e-Pub 2015. PMID: 25315073.
289. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A, Clinical Oncology ASO. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654-6, 2015. e-Pub 2015. PMID: 25605844.
290. Nastoupil LJ, Shenoy PJ, Ambinder A, Koff JL, Nooka AK, Waller EK, Langston A, Seward M, Kaufman JL, Bernal-Mizrachi L, King N, Lechowicz MJ, Lonial S, Sinha R, Flowers CR. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma 56(2):383-9, 2015. e-Pub 2015. PMID: 24828864.
291. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 13(4):219-25, 2014. e-Pub 2014. PMID: 25306485.
292. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211-7, 2014. e-Pub 2014. PMID: 25193992.
293. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124(15):2354-61, 2014. e-Pub 2014. PMID: 25161267.
294. Smedby KE, Sampson JN, Turner JJ, Slager SL, Maynadié M, Roman E, Habermann TM, Flowers CR, Berndt SI, Bracci PM, Hjalgrim H, Weisenburger DD, Morton LM. Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):76-86, 2014. e-Pub 2014. PMID: 25174028.
295. Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM, Feldman AL, Lightfoot T, Boffetta P, Melbye M, Lan Q, Sampson JN, Morton LM, Zhang Y, Weisenburger DD. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):66-75, 2014. e-Pub 2014. PMID: 25174027.
296. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):130-44, 2014. e-Pub 2014. PMID: 25174034.
297. Linet MS, Vajdic CM, Morton LM, de Roos AJ, Skibola CF, Boffetta P, Cerhan JR, Flowers CR, de Sanjosé S, Monnereau A, Cocco P, Kelly JL, Smith AG, Weisenburger DD, Clarke CA, Blair A, Bernstein L, Zheng T, Miligi L, Clavel J, Benavente Y, Chiu BC. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):26-40, 2014. e-Pub 2014. PMID: 25174024.
298. Cerhan JR, Kricker A, Paltiel O, Flowers CR, Wang SS, Monnereau A, Blair A, Dal Maso L, Kane EV, Nieters A, Foran JM, Miligi L, Clavel J, Bernstein L, Rothman N, Slager SL, Sampson JN, Morton LM, Skibola CF. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):15-25, 2014. e-Pub 2014. PMID: 25174023.
299. El Rassi F, Ward KC, Flowers CR, Heffner LT, Waller EK, Winton EF, Vaughn J, Hill BG, Langston A, Nooka A, Arellano M, Khoury HJ. Incidence and geographic distribution of adult acute leukemia in the state of Georgia. South Med J 107(8):497-500, 2014. e-Pub 2014. PMID: 25084186.
300. Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120(12):1830-7, 2014. e-Pub 2014. PMID: 24668580.
301. Nooka AK, Johnson HR, Kaufman JL, Flowers CR, Langston A, Steuer C, Graiser M, Ali Z, Shah NN, Rangaraju S, Nickleach D, Gao J, Lonial S, Waller EK. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20(6):852-857, 2014. e-Pub 2014. PMID: 24607557.
302. Han X, Jemal A, Flowers CR, Sineshaw H, Nastoupil LJ, Ward E. Insurance status is related to diffuse large B-cell lymphoma survival. Cancer 120(8):1220-7, 2014. e-Pub 2014. PMID: 24474436.
303. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008-18, 2014. e-Pub 2014. PMID: 24450858.
304. Langston AA, Prichard JM, Muppidi S, Nooka A, Lechowicz MJ, Lonial S, Sinha R, Graiser M, Kaufman JL, Khoury HJ, Flowers CR, Waller EK. Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone Marrow Transplant 49(2):185-9, 2014. e-Pub 2014. PMID: 24162613.
305. Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH, Lonial S. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer 119(23):4119-28, 2013. e-Pub 2013. PMID: 24005889.
306. Martin P, Byrtek M, Dawson K, Ziemiecki R, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer 119(23):4129-36, 2013. e-Pub 2013. PMID: 24006156.
307. Sinha R, Shenoy PJ, King N, Lechowicz MJ, Bumpers K, Hutcherson D, Arellano M, Langston A, Kaufman J, Heffner LT, Waller EK, Nooka A, Flowers CR, Lonial S. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 13(6):657-63, 2013. e-Pub 2013. PMID: 24094894.
308. Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31(32):4132-9, 2013. e-Pub 2013. PMID: 24043736.
309. Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C, Lerner S, Sharman J, Grinblatt D, Flinn IW, Kozloff M, Swern AS, Street TK, Sullivan KA, Harding G, Khan ZM. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer 21(10):2853-60, 2013. e-Pub 2013. PMID: 23748484.
310. Bulka C, Nastoupil LJ, McClellan W, Ambinder A, Phillips A, Ward K, Bayakly AR, Switchenko JM, Waller L, Flowers CR. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma. Cancer 119(18):3309-17, 2013. e-Pub 2013. PMID: 23896932.
311. Harvey RD, Kaufman JL, Johnson HR, Nooka A, Vaughn L, Flowers CR, Khoury HJ, Lechowicz MJ, Langston AA, Lonial S, Waller EK. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant 19(9):1393-5, 2013. e-Pub 2013. PMID: 23764455.
312. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 119(8):1570-7, 2013. e-Pub 2013. PMID: 23341329.
313. Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma 54(4):752-9, 2013. e-Pub 2013. PMID: 23004352.
314. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(6):794-810, 2013. e-Pub 2013. PMID: 23319691.
315. Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24(2):441-8, 2013. e-Pub 2013. PMID: 23041589.
316. Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N, Brawley OW, Lipscomb J, Lechowicz MJ, Sinha R, Grover RS, Bernal-Mizrachi L, Kowalski J, Donnellan W, The A, Reddy V, Jaye DL, Foran J. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma 54(2):268-76, 2013. e-Pub 2013. PMID: 22800091.
317. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 110(4):1398-403, 2013. e-Pub 2013. PMID: 23292937.
318. Kaufman JL, Flowers CR, Rados KD, Calandra GB, Vose JM, Hewes LB, Lonial S, Langston AA, Khoury HJ, Lechowicz MJ, Waller EK. A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion 53(1):76-84, 2013. e-Pub 2013. PMID: 22624594.
319. Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. Int J Radiat Oncol Biol Phys 86:569-577, 2013. e-Pub 2013.
320. Lonial S, Akhtari M, Kaufman J, Torre C, Lechowicz MJ, Flowers C, Sinha R, Khoury HJ, Langston AA, Waller EK. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biol Blood Marrow Transplant 19:460-467, 2013. e-Pub 2013.
321. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321-5, 2012. e-Pub 2012. PMID: 23143597.
322. Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer 118(19):4842-50, 2012. e-Pub 2012. PMID: 22434428.
323. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30(27):3368-75, 2012. e-Pub 2012. PMID: 22915662.
324. Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21(9):1520-30, 2012. e-Pub 2012. PMID: 22771484.
325. Muringampurath-John D, Jaye DL, Flowers CR, Saxe D, Chen Z, Lechowicz MJ, Weisenburger DD, Bast M, Arellano ML, Bernal-Mizrachi L, Heffner LT, McLemore M, Kaufman JL, Winton EF, Lonial S, Armitage JO, Khoury HJ. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol 158(5):608-14, 2012. e-Pub 2012. PMID: 22758202.
326. Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, Flowers CR, Waller EK. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 18(8):1287-94, 2012. e-Pub 2012. PMID: 22370160.
327. Sinha R, Kaufman JL, Khoury HJ, King N, Shenoy PJ, Lewis C, Bumpers K, Hutchison-Rzepka A, Tighiouart M, Heffner LT, Lechowicz MJ, Lonial S, Flowers CR. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer 118(14):3538-48, 2012. e-Pub 2012. PMID: 22535574.
328. Sinha R, Nastoupil L, Flowers CR. Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer 2012(2):87-98, 2012. e-Pub 2012. PMID: 23532092.
329. Muringampurath-John D, Flowers CR, Toscano M, Zhengjia C, Kaufman JL, Arellano M, Bernal-Mizrachi L, Heffner LT, Lechowicz MJ, McLemore M, Winton E, Jaye DL, Lonial S, Khoury HJ. Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leuk Lymphoma 53(4):725-7, 2012. e-Pub 2012. PMID: 21888615.
330. Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 11(6):498-506, 2011. e-Pub 2011. PMID: 21889433.
331. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 51(10):2175-82, 2011. e-Pub 2011. PMID: 21492180.
332. Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?. Int J Radiat Oncol Biol Phys 81(1):175-80, 2011. e-Pub 2011. PMID: 20732769.
333. Renfroe H, Arnold M, Vaughn L, Harvey RD, Hamilton E, Lonial S, Khoury HJ, Kaufman JL, Lechowicz MJ, Flowers CR, Waller EK. A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion 51(8):1779-83, 2011. e-Pub 2011. PMID: 21332729.
334. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787-94, 2011. e-Pub 2011. PMID: 21632504.
335. Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, Lipscomb J, Flowers CR. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117(11):2530-40, 2011. e-Pub 2011. PMID: 24048801.
336. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol 8(5):302-8, 2011. e-Pub 2011. PMID: 21531305.
337. Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol 2011:725219, 2011. e-Pub 2011. PMID: 21197477.
338. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol 2011:623924, 2011. e-Pub 2011. PMID: 22084700.
339. David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, Marcus AI, Sun SY, Boise LH, Lonial S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 116(24):5285-8, 2010. e-Pub 2010. PMID: 20844234.
340. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, Lugar PL, Mann KP, Flowers CR, Bernal-Mizrachi L, Naresh KN, Evens AM, Gordon LI, Luftig M, Friedman DR, Weinberg JB, Thompson MA, Gill JI, Liu Q, How T, Grubor V, Gao Y, Patel A, Wu H, Zhu J, Blobe GC, Lipsky PE, Chadburn A, Dave SS, Research Consortium HM. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood 116(23):e118-27, 2010. e-Pub 2010. PMID: 20733160.
341. Akhtari M, Giver CR, Ali Z, Flowers CR, Gleason CL, Hillyer CD, Kaufman J, Khoury HJ, Langston AA, Lechowicz MJ, Lonial S, Renfroe HM, Roback JD, Tighiouart M, Vaughn L, Waller EK. Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion 50(11):2424-31, 2010. e-Pub 2010. PMID: 20529004.
342. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 16(20):5079-86, 2010. e-Pub 2010. PMID: 20739431.
343. Tran H, Arellano M, Chamsuddin A, Flowers C, Heffner LT, Langston A, Lechowicz MJ, Tindol A, Waller E, Winton EF, Khoury HJ. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma 51(8):1473-7, 2010. e-Pub 2010. PMID: 20443681.
344. Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?. Clin Lymphoma Myeloma Leuk 10(4):270-7, 2010. e-Pub 2010. PMID: 20709663.
345. Berry J, Caplan L, Davis S, Minor P, Counts-Spriggs M, Glover R, Ogunlade V, Bumpers K, Kauh J, Brawley OW, Flowers C. A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer 116(3):713-22, 2010. e-Pub 2010. PMID: 19950126.
346. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 27(30):5023-30, 2009. e-Pub 2009. PMID: 19770386.
347. Galloway RL, Levett PN, Tumeh JW, Flowers CR. Assessing cost effectiveness of empirical and prophylactic therapy for managing leptospirosis outbreaks. Epidemiol Infect 137(9):1323-32, 2009. e-Pub 2009. PMID: 19161641.
348. Huang T, Shenoy PJ, Sinha R, Graiser M, Bumpers KW, Flowers CR. Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform 8:45-64, 2009. e-Pub 2009. PMID: 19492074.
349. Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202-8, 2009. e-Pub 2009. PMID: 19204203.
350. Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer. Am J Clin Oncol 32(1):49-55, 2009. e-Pub 2009. PMID: 19194125.
351. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 9:9, 2009. e-Pub 2009. PMID: 19144138.
352. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse 3:41-51, 2009. e-Pub 2009. PMID: 24357929.
353. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 49(11):2099-107, 2008. e-Pub 2008. PMID: 19021052.
354. Murali S, Winton E, Waller EK, Heffner LT, Lonial S, Flowers C, Kaufman J, Arellano M, Lechowicz MJ, Mann KP, Khoury HJ, Langston AA. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone Marrow Transplant 42(8):529-34, 2008. e-Pub 2008. PMID: 18622414.
355. Ninan MJ, Flowers CR, Roback JD, Arellano ML, Waller EK. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 13(8):895-904, 2007. e-Pub 2007. PMID: 17640593.
356. Thornton JG, Morris AM, Thornton JD, Flowers CR, McCashland TM. Racial variation in colorectal polyp and tumor location. J Natl Med Assoc 99(7):723-8, 2007. e-Pub 2007. PMID: 17668638.
357. Graiser M, Moore SG, Victor R, Hilliard A, Hill L, Keehan MS, Flowers CR. Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. Cancer Inform 3:149-58, 2007. e-Pub 2007. PMID: 19455241.
358. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK, Kaufman J. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 47(4):629-35, 2007. e-Pub 2007. PMID: 17381621.
359. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 10(1):23-31, 2007. e-Pub 2007. PMID: 17261113.
360. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 13(1):116-23, 2007. e-Pub 2007. PMID: 17222760.
361. Kahn ST, Flowers C, Lechowicz MJ, Hollenbach K, Johnstone PA. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 66(4):961-5, 2006. e-Pub 2006. PMID: 17145526.
362. Lonial S, Arellano M, Hutcherson D, Langston A, Flowers C, Heffner LT, Winton E, Jo Lechowicz M, Waller EK. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leuk Lymphoma 47(10):2155-62, 2006. e-Pub 2006. PMID: 17071490.
363. Kahn ST, Flowers CR, Lechowicz MJ, Hollenbach K, Johnstone PA. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J 11(5):425-31, 2005. e-Pub 2005. PMID: 16259874.
364. Kao LS, Flowers C, Flum DR. Prophylactic cholecystectomy in transplant patients: a decision analysis. J Gastrointest Surg 9(7):965-72, 2005. e-Pub 2005. PMID: 16137593.
365. Tumeh JW, Moore SG, Shapiro R, Flowers CR. Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 5(2):153-62, 2005. e-Pub 2005. PMID: 19807571.
366. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104(5):1550-8, 2004. e-Pub 2004. PMID: 15150081.
367. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104(4):961-8, 2004. e-Pub 2004. PMID: 15113759.
368. Morris AM, Flowers CR, Morris KT, Schmidt WA, Pommier RF, Vetto JT. Comparing the cost-effectiveness of the triple test score to traditional methods for evaluating palpable breast masses. Med Care 41(8):962-71, 2003. e-Pub 2003. PMID: 12886175.
369. Flum DR, Flowers C, Veenstra DL. A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg 196(3):385-93, 2003. e-Pub 2003. PMID: 12648690.
370. Flowers CR, Garber AM, Bergen MR, Lenert LA. Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems. Proc AMIA Annu Fall Symp:223-7, 1997. e-Pub 1997. PMID: 9357621.
371. King, R, Villeneuve, E, Post, L, Flowers, C, Moonshine A, K. Aesthetic preference and DSM-IIIR personality disorders. Personality and Individual Difference 18(6):797-799, 1995. e-Pub 1995.
372. Lenert, LA, Michelson, D, Flowers A, C. IMPACT: An object-oriented graphical environment for construction of multimedia patient interviewing software. Proc Annu Symp Comput Appl Med Care:319-323, 1995. e-Pub 1995.

Invited Articles

1. Goodman A. Expert Point of View: Christopher Flowers, MD. The Asco Post, 2020. e-Pub 2020.
2. Aleynick M, Svensson-Arvelund J, Flowers CR, Marabelle A, Brody JD. Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection. Clin Cancer Res. e-Pub 2019. PMID: 31123052.
3. Braga CC, Taplitz RA, Flowers CR. Clinical Implications of Febrile Neutropenia Guidelines in the Cancer Patient Population. J Oncol Pract 15(1):25-26, 2019. e-Pub 2019. PMID: 30629901.
4. Ç Ç, Terawaki H, Chen Q, Rai A, Ayer T, Flowers CR. Microsimulation Modeling in Oncology. JCO Clin Cancer Inform 2:1-11, 2018. e-Pub 2018. PMID: 30652551.
5. Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology Am Soc Hematol Educ Program 2018(1):189-193, 2018. e-Pub 2018. PMID: 30504309.
6. Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematology Am Soc Hematol Educ Program 2018(1):194-199, 2018. e-Pub 2018. PMID: 30504310.
7. Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology Am Soc Hematol Educ Program 2018(1):185-188, 2018. e-Pub 2018. PMID: 30504308.
8. Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. Lancet Haematol 5(11):e508-e509, 2018. e-Pub 2018. PMID: 29907551.
9. McCullough LE, Flowers CR. Identifying and Addressing Disparities in Survival Outcomes for Rural Patients with Cancer. JAMA Netw Open 1(4):e181243, 2018. e-Pub 2018. PMID: 30646109.
10. Hall KH, Panjic EH, Valla K, Flowers CR, Cohen JB. How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis. Oncology (Williston Park) 32(6):303-9, 2018. e-Pub 2018. PMID: 29940062.
11. Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs 27(6):513-522, 2018. e-Pub 2018. PMID: 29855199.
12. Rosand CB, Valla K, Flowers CR, Koff JL. Effective management strategies for patients with marginal zone lymphoma. Future Oncol 14(12):1213-1222, 2018. e-Pub 2018. PMID: 29260925.
13. Taplitz RA, Kennedy EB, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary. J Oncol Pract 14(4):250-255, 2018. e-Pub 2018. PMID: 29517953.
14. Allen PB, Flowers CR. Balancing patient value and payer cost in hematologic malignancies: can it be done?. Expert Rev Pharmacoecon Outcomes Res 18(2):123-126, 2018. e-Pub 2018. PMID: 29486601.
15. Chang A, Schlafer D, Flowers CR, Allen PB. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opin Investig Drugs 27(1):55-70, 2018. e-Pub 2018. PMID: 29228840.
16. Jordan J, Goldstein JS, Jaye DL, Gurcan M, Flowers CR, Cooper LAD. Informatics Approaches to Address New Challenges in the Classification of Lymphoid Malignancies. JCO Clin Cancer Inform 2, 2018. e-Pub 2018. PMID: 30637363.
17. Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol 28(9):2094-2106, 2017. e-Pub 2017. PMID: 28430865.
18. Ward EM, Flowers CR, Gansler T, Omer SB, Bednarczyk RA. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin 67(5):398-410, 2017. e-Pub 2017. PMID: 28753241.
19. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF. American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. J Clin Oncol 35(22):2576-2579, 2017. e-Pub 2017. PMID: 28459634.
20. Greenwell IB, Flowers CR, Blum KA, Cohen JB. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. Expert Rev Anticancer Ther 17(3):271-279, 2017. e-Pub 2017. PMID: 28112970.
21. Winkfield KM, Flowers CR, Mitchell EP. Making the Case for Improving Oncology Workforce Diversity. Am Soc Clin Oncol Educ Book 37:18-22, 2017. e-Pub 2017. PMID: 28561643.
22. Koff JL, Flowers CR. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev Hematol 9(6):553-61, 2016. e-Pub 2016. PMID: 27098121.
23. Glass S, Phan A, Williams JN, Flowers CR, Koff JL. Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies. Discov Med 21(115):181-8, 2016. e-Pub 2016. PMID: 27115168.
24. Koff JL, Chihara D, Phan A, Nastoupil LJ, Williams JN, Flowers CR. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes. Curr Hematol Malig Rep 10(3):244-55, 2015. e-Pub 2015. PMID: 26104907.
25. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther 15(5):531-44, 2015. e-Pub 2015. PMID: 25864967.
26. Shi Z, Esiashvili N, Flowers C, Das S, Khan MK. Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. Leuk Lymphoma 54(10):2122-30, 2013. e-Pub 2013. PMID: 23445367.
27. Nastoupil LJ, Sinha R, Flowers CR. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Rev Anticancer Ther 13(9):1089-108, 2013. e-Pub 2013. PMID: 23919536.
28. Cohen JB, Flowers CR. Peripheral T-cell lymphoma: what's the role for transplant?. Oncology (Williston Park) 27(9):891-2, 2013. e-Pub 2013. PMID: 24282986.
29. Nastoupil LJ, Flowers CR. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol 9(12):S85-S92, 2012. e-Pub 2012. PMID: 23316119.
30. Nastoupil L, Sinha R, Hirschey A, Flowers CR. Considerations in the initial management of follicular lymphoma. Community Oncol 9(11):S53-S60, 2012. e-Pub 2012. PMID: 23544009.
31. Chen Q, Ayer T, Nastoupil LJ, Seward M, Zhang H, Sinha R, Flowers CR. Initial management strategies for follicular lymphoma. Int J Hematol Oncol 1(1):35-45, 2012. e-Pub 2012. PMID: 23476737.
32. Nastoupil LJ, Rose AC, Flowers CR. Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 26(5):488-95, 2012. e-Pub 2012. PMID: 22730604.
33. Flowers CR, Nastoupil LJ, Bernal-Mizrachi L, Rose AC, Sinha R. New Challenges in the Management of Diffuse Large B-Cell Lymphoma. Treat Strategies Hematol 2(1):68-73, 2012. e-Pub 2012. PMID: 23805376.
34. Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR. Exploring risk factors for follicular lymphoma. Adv Hematol 2012:626035, 2012. e-Pub 2012. PMID: 23028387.
35. Sinha R, DeJoubner N, Flowers C. Novel agents for diffuse large B-cell lymphoma. Expert Opin Investig Drugs 20(5):669-80, 2011. e-Pub 2011. PMID: 21443388.
36. Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR. Idiotype vaccine strategies for treatment of follicular lymphoma. Future Oncol 7(1):111-22, 2011. e-Pub 2011. PMID: 21174542.
37. Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. Expert Opin Biol Ther 11(1):31-40, 2011. e-Pub 2011. PMID: 21073355.
38. Maggioncalda A, Malik N, Shenoy P, Smith M, Sinha R, Flowers CR. Clinical, molecular, and environmental risk factors for hodgkin lymphoma. Adv Hematol 2011:736261, 2011. e-Pub 2011. PMID: 21127715.
39. Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 10(6):414-23, 2010. e-Pub 2010. PMID: 21156459.
40. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60(6):393-408, 2010. e-Pub 2010. PMID: 21030533.
41. Flowers CR. Improving our use and understanding of antibodies in B-cell lymphomas. Oncology (Williston Park) 24(2):176-7, 2010. e-Pub 2010. PMID: 20361468.
42. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22(8):481-93, 2004. e-Pub 2004. PMID: 15217305.
43. Flowers, CR, Veenstra, DL. Will Pharmacogenomics in Oncology be Cost-Effective?. Oncology Economics 1(11):26-33, 2000. e-Pub 2000.
44. King, RJ, Flowers, CR, Stewart A, S. NIDA Res Monogr. Neurochemical models of temperament: applications to cocaine induced craving 159:228-263, 1996. e-Pub 1996.

Review Articles

1. Di, M, Maurer, MJ, Flowers, CR. End points and outcomes in follicular lymphoma. Blood 146(15):1802-1811, 2025. e-Pub 2025. PMID: 40019453.
2. Jiang, JY, Li, A, Romero, A, Flowers, CR, Nze, CC. Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials. Oncologist 30(6), 2025. e-Pub 2025. PMID: 40554671.
3. Akkad, N, Flowers, CR. Patient-Reported Outcome Measures (PROMS) in Lymphoma. Current Oncology 32(5), 2025. e-Pub 2025. PMID: 40422524.
4. Flowers, CR, Anantha, RW, Leautaud, V, Desai, PM, Donald, CE, Hildebrandt, MA, Koff, JL, Tamimi, RM, Cozen, W, Nze, CC, Melnick, AM. Addressing Health Disparities in Hematologic Malignancies. Blood Cancer Discovery 6(2):79-93, 2025. e-Pub 2025. PMID: 39898759.
5. Rollins, MR, Warsame, R, Smith, M, Molina, A, Rouce, R, Avalos, B, Johnson, CS, Lopez, JA, Thompson, AA, Fanning, L, Frustace, P, Roche, K, van Havre, N, Mack, D, Flowers, CR, Terrell, DR. American Society of Hematology. Blood Advances 8(24):6237-6247, 2024. e-Pub 2024. PMID: 39570294.
6. Chihara, D, Hobbs, BP, Maurer, MJ, Flowers, CR. Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma. Pharmacoepidemiology 3(3):252-264, 2024. e-Pub 2024.
7. Chihara D, Nastoupil LJ, Flowers CR. Clinical approaches for integrating machine learning for patients with lymphoma: Current strategies and future perspectives. Br J Haematol 202(2):219-229, 2023. e-Pub 2023. PMID: 37170487.
8. Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, Constine LS. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. Int J Radiat Oncol Biol Phys 111(1):36-44, 2021. e-Pub 2021. PMID: 33774076.
9. Moubadder L, McCullough LE, Flowers CR, Koff JL. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiol Biomarkers Prev 29(10):1844-1855, 2020. e-Pub 2020. PMID: 32727723.
10. Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res 19(6):645-661, 2019. e-Pub 2019. PMID: 31623476.
11. Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK. Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer 125(2):185-193, 2019. e-Pub 2019. PMID: 30480777.
12. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36(30):3043-3054, 2018. e-Pub 2018. PMID: 30179565.
13. Koff JL, Li JX, Zhang X, Switchenko JM, Flowers CR, Waller EK. Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer 124(11):2327-2336, 2018. e-Pub 2018. PMID: 29579330.
14. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):1443-1453, 2018. e-Pub 2018. PMID: 29461916.
15. Lin RJ, Behera M, Diefenbach CS, Flowers CR. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. Blood 130(20):2180-2185, 2017. e-Pub 2017. PMID: 28814386.
16. Zeichner SB, Goldstein DA, Kohn C, Flowers CR. Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. J Gastrointest Oncol 8(3):513-523, 2017. e-Pub 2017. PMID: 28736638.
17. Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology (Williston Park) 30(12):1099-103, 1106-8, 2016. e-Pub 2016. PMID: 27987203.
18. Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS, Radiation Oncology–Lymphoma EPO. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol 39(6):535-544, 2016. e-Pub 2016. PMID: 27643717.
19. Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS, Radiation OncologyLymphoma EPO. ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Am J Clin Oncol 39(4):384-95, 2016. e-Pub 2016. PMID: 27299425.
20. Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. Clin Colorectal Cancer 15(1):1-6, 2016. e-Pub 2016. PMID: 26541320.
21. Wang SS, Vajdic CM, Linet MS, Slager SL, Voutsinas J, Nieters A, de Sanjose S, Cozen W, Alarcón GS, Martinez-Maza O, Brown EE, Bracci PM, Lightfoot T, Turner J, Hjalgrim H, Spinelli JJ, Zheng T, Morton LM, Birmann BM, Flowers CR, Paltiel O, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Foretova L, Staines A, Davis S, Severson R, Cerhan JR, Breen EC, Lan Q, Brooks-Wilson A, De Roos AJ, Smith MT, Roman E, Boffetta P, Kricker A, Zhang Y, Skibola C, Chanock SJ, Rothman N, Benavente Y, Hartge P, Smedby KE. Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. Am J Epidemiol 181(6):406-21, 2015. e-Pub 2015. PMID: 25713336.
22. Goldstein DA, Shaib WL, Flowers CR. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park) 29(3):175-83, 2015. e-Pub 2015. PMID: 25783977.
23. Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 14(6):460-467.e2, 2014. e-Pub 2014. PMID: 25052052.
24. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer 61(7):1305-12, 2014. e-Pub 2014. PMID: 24616347.
25. Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park) 27(8):786-94, 2013. e-Pub 2013. PMID: 24133827.
26. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, Clinical Practice ASOCO. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189-204, 2013. e-Pub 2013. PMID: 23669224.
27. Wender R, Fontham ET, Barrera E, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, Walter L, Wolf AM, Brawley OW, Smith RA. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 63(2):107-17, 2013. e-Pub 2013. PMID: 23315954.
28. Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 12(6):393-9, 2012. e-Pub 2012. PMID: 23158095.
29. Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk 11(5):379-84, 2011. e-Pub 2011. PMID: 21729690.
30. Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer 34(3):211-27, 2010. e-Pub 2010. PMID: 20541059.
31. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW, Clinical Oncology ASO. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490-505, 2007. e-Pub 2007. PMID: 17968019.
32. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci 938:328-37; discussion 337-9, 2001. e-Pub 2001. PMID: 11458521.
33. Flowers CR, Melmon KL. Clinical investigators as critical determinants in pharmaceutical innovation. Nat Med 3(2):136-43, 1997. e-Pub 1997. PMID: 9018224.

Other Articles

1. Yan, F, Jiang, C, Jordan, A, Che, Y, Liu, Y, Cai, Q, Xue, Y, Li, Y, McIntosh, J, Chen, Z, Vargas, J, Nie, L, Yao, Y, Lee, H, Wang, W, Bigcal, J, Badillo, M, Meena, JK, Flowers, CR, Zhou, J, Zhao, Z, Simon, LM, Wang, L Correction. Experimental Hematology and Oncology 15(1), 2026.
2. Singh AP, Xiao L, O'Brien BJ, Blondeau CE, Flowers CR, Bruera E, Morris VK, Shah AY Erratum: Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study. JCO Oncol Pract 22(1):174, 2026. PMID: 40446183.
3. Nze C, Flowers CR Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385. Hematology Am Soc Hematol Educ Program 2025(1):708, 2025. PMID: 41348053.
4. Morschhauser, F, Salles, G, Sehn, L, Herrera, AF, Friedberg, JW, Trneny, M, Lenz, G, Sharman, JP, Herbaux, C, Burke, JM, Matasar, MJ, Collins, G, Mehta-Shah, N, Oberic, L, Chauchet, A, Jurczak, W, Song, Y, Pinto, A, Rai, S, Izutsu, K, Greil, R, Mykhalska, L, Bergua-Burgués, JM, Cheung, MC, Shin, HJ, Hapgood, G, Munhoz, E, Abrisqueta, P, Gau, JP, Jiang, Y, McCall, B, Chohan, S, Sugidono, M, Yan, M, Lee Batlevi, C, Tilly, H, Flowers, CR Erratum. Journal of Clinical Oncology, 2025. PMID: 41264903.
5. Zhang, S, Jiang, VC, Han, G, Hao, D, Lian, J, Liu, Y, Cai, Q, Zhang, RJ, McIntosh, J, Wang, R, Dang, M, Dai, E, Wang, Y, Santos, DA, Badillo, M, Leeming, A, Chen, Z, Hartig, K, Bigcal, J, Zhou, J, Kanagal-Shamanna, R, Ok, CY, Lee, H, Steiner, RE, Zhang, J, Song, X, Nair, R, Ahmed, S, Rodriquez, A, Thirumurthi, S, Jain, P, Wagner-Bartak, N, Hill, H, Nomie, K, Flowers, CR, Futreal, A, Wang, L, Wang, L Author Correction. Nature communications 15(1), 2024. PMID: 39375332.

Editorials

1. Funk CR, Petersen CT, Jagirdar N, Ravindranathan S, Jaye DL, Flowers CR, Langston A, Waller EK. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. Int J Mol Sci 19(12), 2018. PMID: 30572564.
2. Flowers CR, Ramsey SD. What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?. J Clin Oncol:JCO2018793570. PMID: 30277825.
3. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary. J Oncol Pract:JOP1800366. PMID: 30179525.
4. Sargent DJ, Shi Q, Flowers CR, Schmitz N, Habermann TM, Flament J, Fu T, Coiffier B, group S. The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist 22(12):1415-1418, 2017. PMID: 28798271.
5. Koff JL, Flowers CR. Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?. Cancer 123(17):3222-3225, 2017. PMID: 28464215.
6. Marron TU, Ronner L, Martin PE, Flowers CR, Brody JD. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Immunotherapy 8(11):1335-1346, 2016. PMID: 27993085.
7. Goldstein DA, Howard DH, Flowers CR. Perspectives in Oncology Drug Pricing-Reply. JAMA Oncol 2(3):402-3, 2016. PMID: 26967189.
8. Flowers CR, Skibola CF. Identifying risk factors for B-cell lymphoma. Blood 127(1):10-1, 2016. PMID: 26744436.
9. Williams JN, Koff JL, Flowers CR. Reply to Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma. Cancer 121(20):3748, 2015. PMID: 26110283.
10. Williams JN, Rai A, Flowers CR. Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma. Cancer 121(16):2858-9, 2015. PMID: 25925878.
11. Khan MK, Esiashvili N, Flowers C. Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era. Acta Haematol 134(2):109-10, 2015. PMID: 25925483.
12. Shams SR, Goldstein DA, Kaufman JL, MacKelfresh J, Flowers CR, Langston AA. Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema. Clin Lymphoma Myeloma Leuk 14(6):e213-5, 2014. PMID: 25065780.
13. Flowers CR, Nastoupil LJ. Socioeconomic disparities in lymphoma. Blood 123(23):3530-1, 2014. PMID: 24904097.
14. Flowers CR, Karten C. Communicating safe outpatient management of Fever and neutropenia. J Oncol Pract 9:207-210, 2013.
15. Flowers CR, Pro B. Racial differences in chronic lymphocytic leukemia. Digging deeper. Cancer 119(20):3593-3595, 2013.
16. Bergsagel E, PL, Erba HP, HP, Flowers, CR. Advancing Treatment Paradigms in Hematologic Malignancies: Highlights from the 50th ASH Annual Meeting. Educational Concepts Group Online CME Activity, 2009.
17. Graiser, M, Hill, L, Keehan, MS, Labonté, S, Flowers, C. Building an Integrated Information System for Cancer Research: A Collaborative Approach. American Medical Informatics Association Annual Symposium, 2005.

Book Chapters

1. Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Flowers CR. Non-Hodgkin Lymphoma in Adults. In: American Cancer Society Textbook of Oncology. First. John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA, 444-462, 2018.
2. Gladney SP, Flowers, C, Langston A, and Lonial S. Mantle Cell Lymphoma: Current and Future Therapies. In: Cancer Research at the Leading Edge, Ed. Ignatius Martakis, 2007.
3. Kaklamani VG, Flowers C, Williams S, O’Regan R. Use of Bone Stem Cell Transplantation in Breast Cancer. In: Surgery of the Breast: Principles and Art. Scott L Spear, Shawna C Willey, Geoffrey L Robb, Dennis C Hammond, and Maurice Y Nahabedian eds., Lippincott Williams & Wilkins, Hagerstown, MD, 2005.
4. Flowers CR, Melmon KL. Clinical champions as critical determinants of drug development. In: Pharmaceutical Innovation: Revolutionizing Human Health. Ralph Landau, 1999.

Letters to the Editor

1. Taplitz RA, Kennedy EB, Flowers CR. Reply to M.A. Slavin et al. J Clin Oncol 37: 1140-1141, 2019.
2. Shi Q, Flowers CR. Reply to H.J.A. Adams et al. J Clin Oncol 37: 526-527, 2019.
3. Taplitz RA, Kennedy EB, Flowers CR. Reply to J.A. Talcott. J Clin Oncol: JCO2018793141.
4. Flowers, C, Lechowicz, MJ, Johnstone, PA. In reply to Drs. Nieder and Andratschke. Int J Radiat Oncol Biol Phys 67: 1278, 2007.
5. Santos, EC, Sessions, J, Hutcherson, D, Flowers, C, Langston A, Waller A, EK. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar Experience. Biol Blood Marrow Transplant 13: 746-747, 2007.
6. Flowers, CR, Melmon, KL. Cyclosporin and the clinical investigator. Nature Medicine 3: 590, 1997.